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ABSTRACT OF DISSERTATION

HORMONAL MODULATION OF THE BEHAVIORAL EFFECTS OF TRIAZOLAM
There is accumulating evidence from many directions indicating that gender
plays a critical role in drug abuse. Biological factors, including gonadal sex hormones,
contribute in a significant although incompletely understood manner, to gender
differences in drug abuse. Female sex hormones have been shown to affect central
nervous system function and modulate the effects of drugs of abuse. For example,
GABAA receptor function is positively modulated by progesterone. There is evidence
from preclinical in vitro and in vivo studies as well as some clinical research suggesting
that progesterone and its metabolites may enhance the behavioral effects of
benzodiazepines, which also serve as positive modulators of GABAA receptors.
The three studies presented here utilize within subject designs to assess the role
of progesterone on the discriminative stimulus, subjective, performance and
cardiovascular effects of triazolam, a short-acting benzodiazepine, in healthy,
premenopausal women. The first study examined the effect of menstrual cycle phase on
the discriminative stimulus effects of triazolam (0.00, 0.06, 0.12 and 0.25 mg/70 kg). The
results of this study indicated that when progesterone levels peak (mid luteal phase), the
discriminative stimulus effects of triazolam (0.12 mg/70 kg) are enhanced. The second
study examined the separate and combined effects of a range of acute doses of oral
micronized progesterone (0, 100 and 200 mg) and oral triazolam (0.00, 0.12 and 0.25
mg/70 kg) on the subjective, psychomotor and physiological effects of these
medications, tested under conditions of low circulating sex hormones. The results of this
study indicated that progesterone alone has some short-acting, sedative-like effects and
enhances the subjective and performance effects of triazolam. The final study examined
the effects of progesterone (0 and 100 mg) on the discriminative stimulus effects of
triazolam (0.00, 0.06, 0.12 and 0.25 mg/70 kg), also under conditions of low circulating
sex hormones. The results of this study indicated that the parent hormone progesterone
does not appear to alter sensitivity to the discriminative stimulus effects of triazolam.
Increases in sensitivity to triazolam in studies 1 and 2 may have been the result of
neuroactive progesterone metabolites (e.g., allopregnanolone, TH-DOC), although future
studies will be required to further examine this possibility. Taken together, these studies
help clarify the manner in which the ovarian hormone progesterone and its metabolites
modulate the behavioral effects of the benzodiazepines.
KEYWORDS: Progesterone, Neurosteroid, Benzodiazepine, Women’s health,
Drug Discrimination
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CHAPTER 1
INTRODUCTION
BACKGROUND RESEARCH
There is increasing evidence that the functional effects of drugs differ among
men and women. Greater numbers of men use and abuse illicit drugs than women
(SAMHSA, 2009). However, there are marked differences between men and women in
the relative risk of developing dependence on sedative-hypnotic drugs (e.g.,
benzodiazepines). After initiating sedative-hypnotic drug use, women are significantly
more likely to develop problematic use patterns relative to their male counterparts, such
that women may be nearly twice as likely to develop dependence on these compounds
(Kandel et al., 1998; Anthony et al., 1994). In addition, women are prescribed sedativehypnotic compounds at higher rates than men (Nomura et al., 2006; Howes et al., 1996;
van der Waals et al., 1993; Wysowski & Baum, 1991), take the medications longer once
prescribed (Geiselmann & Linden, 1991), and are more likely to use the medications for
non-medical purposes (Simoni-Wastila et al., 2004).
Gender disparities are undoubtedly influenced by environmental variables (i.e.,
drug availability, socio-cultural variables); however, there is also evidence that gender
differences may be biologically mediated, and perhaps influenced by ovarian hormones.
Ovarian steroid hormones, such as estradiol and progesterone, crucial to peripheral
nervous system function and reproductive health, modulate central nervous system
(CNS) function. The non-genomic CNS actions of these steroids are mediated through
neuronal receptor mechanisms, resulting in rather rapid modulation of the effects of
psychoactive compounds. Although the neurosteroids progesterone and estradiol are
present in men, the circulating blood levels are minimal and stable across time. The
plasma levels of these hormones vary as a function of menstrual cycle phase and are
present at different circulating levels in women.

Since the receptor mechanisms

modulated by steroid hormones overlap with those affected by drugs of abuse, it is
critical to investigate whether ovarian hormones influence the abuse liability of drugs in
women.
Although several sex hormones modulate drug action, a systematic examination
of an individual ovarian hormone is an informative and productive approach, as it
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provides detailed information regarding the relative influence of a single hormone in the
acute effects of a drug. Therefore, the following series of studies focus on the effects of
progesterone.
Progesterone and its primary metabolites, allopregnanolone, pregnanolone and
TH-DOC, modulate neurotransmitter activity via both genomic and non-genomic
mechanisms. The non-genomic effects of these neurosteroids include direct activation of
neuronal

membrane-bound

receptors

and

the

rapid

modulation

of

several

neurotransmitter systems including GABA, dopamine, opiate, glutamate and nicotinic
acetylcholine systems (Pluchino et al., 2006; Lena et al., 1993).

The most well-

characterized and perhaps most influential, of progesterone’s effects are those at the
GABAA receptor complex. Sedative-hypnotic drugs such as the benzodiazepines also
produce

their

effects,

in

large

part,

via

modulation

of

GABA A

receptors.

Allopregnanolone, TH-DOC, and pregnanolone are ligands at extracellular, steroidspecific recognition sites on GABAA receptors, with affinities that are comparable to
those of many benzodiazepines (Paul & Purdy, 1992; Majewska et al., 1986).

In

addition, these neurosteroids dose-dependently increase the effects of benzodiazepines
on GABA-induced Cl- currents, indicating that there is a receptor-level interaction
between benzodiazepines and neurosteroids (Paul & Purdy 1992; Bertz et al., 1995).
The behavioral effects of these neurosteroids also overlap with those engendered by
benzodiazepines.

Through GABAA modulation, neurosteroids can induce anxiolytic,

sedative and antiepileptic effects (Schumacher et al., 1989).
The effects of progesterone and its metabolites on receptor function have been
linked to many of the clinical effects of the hormone, including sedation, memory
impairment, anxiolysis, depression, alcohol dependence, stress reduction and antiseizure effects (Pisu & Serra, 2004; Rhodes et al., 2004; Schumacher & Robert, 2002;
Rupprecht, 2003). Elucidation of the neuropharmacological effects of progesterone may
elucidate some of the biological-mediated underpinnings of gender differences in these
conditions.
Because progesterone metabolites have a direct action at GABA receptor sites, it
is hypothesized that progesterone may potentiate the behavioral effects of GABAergic
drugs. Preclinical studies have demonstrated such an effect. For example, Grant and
colleagues have conducted research using non-human primates (Macaca fascicularis)
and have demonstrated that the discriminative stimulus effects of ethanol are sensitive
to menstrual cycle phase, such that the ethanol generalization curve is shifted to the left
2

during the mid-luteal phase of the menstrual cycle when progesterone levels surge
(Grant et al., 1997, Green et al., 1999). In contrast, menstrual cycle mediation of the
effects of GABAergic drugs in women has not been consistently reported. The
reinforcing and subjective effects of ethanol have been examined across three phases of
the menstrual cycle (early follicular, late follicular, luteal) in normally cycling, healthy
women (Holdstock & de Wit, 2000). These investigators found no changes in alcohol
effects as a function of menstrual cycle phase. The subjective and performance effects
of triazolam have also been examined across three phases of the menstrual cycle
(follicular, periovulatory, and luteal), with no menstrual cycle modulation reported
(Rukstalis & de Wit, 1999). It remains to be seen whether procedures that have been
developed to examine the receptor-mediated effects of drugs, such as the drug
discrimination methodology (e.g., Kamien et al., 1993; Kelly et al., 2003; Colpaert, 1999)
could be used to test the clinical neuropharmacology of progesterone in a more sensitive
manner than has been possible using self-report and performance measures.
Sensitivity to the behavioral effects of benzodiazepines in women also may be
more consistent when levels of neurosteroids are directly manipulated.

When

administered as a pre-treatment, exogenous oral micronized progesterone enhanced the
sedative, memory and performance effects induced by oral triazolam in postmenopausal women (McAuley et al., 1995). In addition, women taking oral birth control
containing both progesterone and estradiol were more sensitive to the performance
impairing effects of alprazolam, lorazepam, and triazolam (Kroboth et al., 1985).
Hormone pre-treatment studies have many methodological advantages over other
approaches.

When a hormone pre-treatment is administered when endogenous

hormones are at nadir levels (e.g., the early follicular phase), it allows for the controlled
examination of the effects of the hormone. In contrast, when drug effects are examined
across the cycle, various hormone levels are in flux, making it difficult to apply a causal
mechanism to a particular hormone. In addition, pre-treatment studies allow for multiple
doses of hormone to be tested and dose-response relationships established. As such, it
is clear that pre-treatment studies hold significant potential for examining the clinical
neuropharmacology of progesterone and to elucidate potential gender differences in
sensitivity to the effects of benzodiazepines.
The purpose of the following series of studies is to determine whether the ovarian
hormone progesterone modulates the behavioral effects of the sedative drug triazolam
using human laboratory methodologies. The first study will determine if elevated levels
3

of progesterone during the mid luteal phase of the menstrual cycle enhances the
discriminative stimulus effects of triazolam, as compared to nadir levels of progesterone
during the early follicular phase (i.e., menstrual cycle modulation of the discriminative
stimulus effects of triazolam).

The second study will examine the independent and

combined subjective and psychomotor effects of exogenous progesterone and triazolam
in healthy adult premenopausal women. The third study will examine whether
exogenous progesterone pretreatment modulates the discriminative stimulus effects of
triazolam.
RATIONALE
The purpose of Study 1 is to determine if the behavioral effects, including the
discriminative stimulus effects, of triazolam are modulated as a function of menstrual
cycle phase. Drug discrimination methodology is incorporated as a primary measure in
this study because there is evidence that drug discrimination may be more sensitive to
hormonal modulation and to the effects of drugs at the receptor level, than self-report
measures alone (Lile et al., 2007; Kelly et al., 2003).

It is hypothesized that the

discriminative stimulus effects of triazolam will be enhanced during the mid-luteal phase,
when progesterone levels are elevated, relative to the early follicular phase, when
progesterone is at nadir levels.

The results of this study will help elucidate the

underpinnings of changes in acute drug effects across the menstrual cycle. However,
given that several hormonal changes occur across the menstrual cycle, it is not possible
to determine from these results if a specific hormone modulates the effect of triazolam.
Instead, these results will provide indirect information about the relationship between the
hormonal array present during specific phases of the menstrual cycle and the behavioral
effects of triazolam.

Specifically, this study will not reveal if the potentiation of the

discriminative stimulus effects of triazolam during the mid-luteal phase reflects
independent or combined effects of progesterone or estradiol modulation of
benzodiazepine effects, since both steroids are elevated during the mid-luteal phase.
Similarly, it will not be possible to determine whether menstrual cycle effects are
associated with acute or repeated exposure to elevated hormones. Thus, it is necessary
to conduct pre-treatment studies to isolate and manipulate the effects of progesterone to
determine if the changes in triazolam effects during the mid-luteal phase are due
specifically to the acute presence of progesterone.
The purpose of Study 2 is to test the behavioral effects of several dose
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combinations of both oral progesterone and triazolam.

This study will examine the

separate and combined behavioral effects of progesterone and triazolam across a range
of doses in order to evaluate the interactive effects of these two compounds. As this is
the first study to examine the independent and combined effects of these two
medications, it is important to establish dose-response relationships. Clinically relevant
doses of progesterone and triazolam are tested in that the progesterone doses will
engender progesterone plasma levels that are consistent with those naturally occurring
across the menstrual cycle (Chakmakjian & Zachariah, 1987; Sofuoglu et al., 2001; de
Wit et al., 2001; Soderpalm et. al., 2004), and the triazolam doses are within the dose
range recommended for therapeutics (Physician’s Desk Reference, 2006). This study
will extend the results of the first study by directly examining the effects of physiological
doses of progesterone, alone and in combination with a dose range of triazolam. It is
hypothesized that progesterone will potentiate the effects of triazolam.
The purpose of Study 3 is to utilize drug discrimination methodology to more
precisely examine the neuropharmacological effects of progesterone, alone and
combination with triazolam, as drug discrimination has been shown to be an effective
tool in examining pharmacological changes mediated by receptor-based interactions
(Colpaert, 1999; Kelly et al., 2003). The results of Study 2 will inform the pretreatment
dose of progesterone to be used in Study 3. It is hypothesized that progesterone
pretreatment will potentiate the discriminative stimulus, and other behavioral effects of
triazolam.
IMPLICATIONS
Overall, understanding the mechanisms by which neurosteroids modulate
neurotransmitters

systems

has

important

clinical

implications.

Neurosteroids,

specifically progesterone metabolites, modulate several behaviors and disease
conditions, as variations in these hormones contribute to predisposing or protecting
individuals from sleep disturbances, anxiety, depression, epilepsy, dementia, and postpartum depression (Bicikova et al., 2000, Ströhle et al., 2003; Romeo et al., 1993;
Murialdo et al., 2001; McCoy et al., 2003; Rupprecht, 2003).

Not only are these

hormones a factor in individual differences in disease processes, variation in
neurosteroid levels also contributes to individual differences in drug effects.

For

example, levels of endogenous progesterone metabolites have been correlated with the
severity of ethanol tolerance and withdrawal, and the efficacy of anxiolytic medications
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(Romeo et al., 1996; 2000; Le Mellédo et al., 2000; Brambilla et al., 2005; Ho et al.,
2004).

As hormones rapidly fluctuate across the menstrual cycle, intra-individual

differences in hormonal modulated drug effects are particularly evident in women. For
example, hormonal changes across the cycle can often necessitate modifications in
doses of anti-epileptics (Reddy, 2009; Herzog et al., 2009; Bäckström, 1976) and
anesthetics (Erden et al., 2005) to properly maintain the condition without adverse side
effects. As such, understanding the role of neurosteroids in drug modulation may lead to
a greater understanding of gender and individual differences in the effects of certain
drugs. Taken together, elucidating the biological underpinnings of the gender differential
observed in abuse and dependence liability may inform gender-specific drug prevention
and treatment strategies.
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CHAPTER 2
STUDY 1: Modulation of the discriminative stimulus effects of triazolam across the
menstrual cycle phase in healthy pre-menopausal women
INTRODUCTION
Progesterone is a positive modulator of the GABAA receptor complex, and its
primary metabolites allopregnanolone, pregnanolone and TH-DOC function as ligands at
extracellular steroid-specific recognition sites on GABAA receptors with affinities that are
comparable to those of many benzodiazepines (Bertz et al., 1995; Paul & Purdy, 1992;
Majewska, 1992; Majewska et al., 1986). Through GABAA modulation, progesterone
induces behavioral effects similar to those engendered by benzodiazepines (e.g.,
anxiolysis, sedation and antiepileptic effects) (Frye, 2007; Rupprecht, 2003; Schumacher
et al., 1989), and changes in progesterone levels across the menstrual cycle have been
shown to modulate the behavioral effects of GABAergic drugs in pre-clinical models.
Grant and colleagues, for example, demonstrated that sensitivity to the discriminativestimulus effects of alcohol was enhanced in non-human primates during the mid-luteal
phase of the menstrual cycle when progesterone levels are elevated compared to the
follicular phase when progesterone levels are minimal (Grant et al., 1997, Green et al.,
1999). In contrast, few changes in the reinforcing or subjective effects of ethanol or
triazolam have been reported across the menstrual cycle in normally cycling, healthy
women (Holdstock & de Wit, 2000; Rukstalis & de Wit, 1999).

Inconsistencies in

menstrual cycle phase modulation of sedative drug effects across studies could be
related to differences in either species or methods used to assess drug effects. The
current study addressed these inconsistencies by examining the discriminative stimulus
effects of triazolam during the mid-luteal and early follicular phases of the menstrual
cycle in normally cycling, healthy women. It was hypothesized that the discriminative
stimulus effects of triazolam would be enhanced during the mid-luteal phase.
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METHOD
Participants
Healthy pre-menopausal women were recruited through local newspaper
advertisements and with flyers posted on a university campus. All potential participants
completed an initial telephone or internet-based screening questionnaire, and an on-site
medical evaluation that included a menstrual history, health questionnaires, blood
chemistry and urinalysis. Eligibility criteria included a minimum of 18 years of age, good
health, reports of intermittent sedative drug use (e.g., alcohol) and regular menstrual
cycles (monitored across two menstrual cycle phases prior to participation). Exclusion
criteria included significant medical history (e.g., cardiovascular, neurological, or major
psychiatric illnesses, including drug or alcohol dependence), regular use of drugs or
alcohol, other than nicotine or caffeine, use of hormonally-based contraceptives,
pregnant or breastfeeding status, or any other condition that for which triazolam
administration would be contraindicated.
Twenty participants met eligibility criteria and initiated the study. Eight participants
withdrew from the study for reasons unrelated to the study protocol, five were
discontinued from the study because they did not acquire the drug discrimination; data
from these thirteen participants were excluded from analyses. Table 1.1 details
demographic variables of participants who were unable to acquire the discrimination and
the participants who successfully acquired the discrimination. None of the variables
examined were consistently related to acquisition (either successful or unsuccessful) of
the discrimination. Seven volunteers completed the study. The participants ranged in
age from 21 to 43 years (median = 30 years), in weight from 47 to 69 kg (median = 60
kg), and drank 1 to 6 alcohol drinks per month (median = 2). One participant was a
smoker (mean of 10 cigarettes per day); however, she abstained from smoking for the
duration of each session.
Design
A double-blind, placebo-controlled, randomized within-subject design was used
to assess the effects of menstrual cycle phase (early follicular and mid luteal), triazolam
dose (training doses: 0.0, and 0.25 mg/70 kg, test doses: 0.06, 0.12 mg/70 kg), and time
(assessments occurring pre-dose, 30, 60, 90, 120 and 150 minutes post-dose) on the
8

discriminative stimulus and other behavioral effects of triazolam.
Participants were instructed to abstain from alcohol and all medications for 24
hours and caffeine and food for 4 hours prior to their scheduled sessions. At the beginning of each session, participants were asked questions about medication use, sleep,
food consumption and health status for the preceding 24 hours. No sessions were cancelled due to reports of atypical activities. Participants then completed a field-sobriety
test, provided a breath sample that was tested for alcohol use (Alco-Sensor III, Intoxi meters, Inc., St. Louis, MO) and provided a urine sample that was tested for amphetamine, barbiturates, benzodiazepines, cocaine, marijuana, methadone, methamphetamine,
MDMA, and opiates (E-Z Split Key Cup, ACON Laboratories, San Diego) and pregnancy
(hCG One Step Pregnancy Test Device, Instant Technologies, Inc., Norfolk, VA).
Assessments used to measure drug effects included a Drug Discrimination Task
(post-dose only), Visual Analog (VAS) and Adjective Rating (ARS) Scales, Digit Symbol
Substitution Task (DSST), and heart rate and blood pressure measurement (Sentry II,
NBS Medical, Costa Mesa, CA).

Drugs
Doses of triazolam were prepared by the University of Kentucky Investigational
Pharmacy. Triazolam (0.00, 0.06, 0.12 and 0.25 mg/70 kg) was prepared in size 0
opaque capsules, with cornstarch filler. Placebo capsules contained only cornstarch
filler. Triazolam doses were delivered orally.

Assessment Tasks
Drug-Discrimination Task
During this task, two circles labeled with a color code (i.e., “Red” and “Blue”) were
displayed on the computer screen, each associated with a training dose condition.
Counters were displayed directly below the circles. A mouse controlled the location of a
cursor on the screen, and mouse button presses with a cursor positioned on a circle
increased the counter associated with that circle according to a fixed-interval 1-sec
schedule. The cursor could alternate across the circles without any consequence under
the fixed-interval schedule (i.e., no change-over-delay). Up to 60 points could be
allocated across the two options. The dependent variable for this task was the percent
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responding on the active drug-appropriate option.
Drug discrimination procedure
Sampling Phase
The sampling phase consisted of four sessions; each of the triazolam training
doses (0.00 and 0.25 mg/70 kg) was administered on two sessions in an alternating
pattern. For every participant, the training doses were associated with a fixed color code
throughout the study, with the color-dose combinations and order of presentation being
randomized across participants. Dose color was identified during drug administration,
and participants were told to associate the effects of the dose with that color. Sampling
sessions were conducted without regard to menstrual cycle phase.
Control Phase
Training doses of triazolam (0.00, 0.25 mg/70 kg) were administered randomly
under double-blind conditions, and participants were not told which dose was
administered until after the last assessment of a session. Acquisition of drug
discrimination was established when ≥ 80% of responses were allocated to the drugappropriate stimulus during the last assessment of the session (150 minutes post-dose)
for 5 consecutive sessions. If the acquisition criterion was not met within 15 sessions,
participation ended. Participants who met criteria did so within 5 to 15 sessions. Control
sessions were conducted without regard to menstrual cycle phase and occurred
immediately following training sessions.
Test Phase
Test Phase sessions were identical to control sessions, except that both training
and test (0.06 and 0.12 mg/70 kg) doses were presented, and sessions were scheduled
only during specific phases of the menstrual cycle. Participants completed 6 sessions
during the early follicular phase of the menstrual cycle (days 1-7 following onset of
menses) and 6 sessions during the mid-luteal phase of their menstrual cycle (days 5-12
following ovulation, as determined using daily urine assessments). During each cycle
phase, each training dose was administered once and each test dose was administered
twice. The order of menstrual cycle phase testing (i.e., whether test sessions began
during the early follicular or mid-luteal phase) was randomized and varied among
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participants. Sessions were scheduled around participants’ availability within each
menstrual cycle phase. Because time during any particular cycle phase was limited,
participants completed the Test Phase across two or three consecutive cycle phases
(i.e., across several months), such that some sessions were consecutive while others
were separated by days or weeks. The length of time that elapsed between Control and
Test Phase sessions varied depending on when participants’ next cycle phase occurred
and ranged from zero days to three weeks.
After the final assessment on every session, participants were told whether a red
dose, a blue dose, or a test dose had been administered. On red and blue dose (i.e.,
training) sessions, participants received $0.04 per point accumulated on the circle
associated with the dose administered on that session.

On test dose sessions,

participants received the average of earnings on training dose sessions, regardless of
point distributions.
VAS
Participants 9 rated items presented individually on the computer by marking a
100-unit line anchored on the extremes by “Not At All” and “Extremely”. Items included
were: Stimulated, Sedated, Anxious, High, Confident, Hungry, Thirsty, Drug Effect, and
Like Drug Effect.
ARS
The Adjective Rating Scale consists of 32 items and contains two subscales:
Sedative and Stimulant (Oliveto et al., 1992).

Participants rated each item using a

numeric keypad to select one of five options: “Not at All”, “A Little Bit”, “Moderately”,
“Quite A Bit” and “Extremely” (scored numerically from 0 to 4, respectively; maximum
score =64).
DSST
Participants completed a 2 minute computerized version of the DSST adopted
from McLeod et al., 1982. The dependent measures for this psychomotor task were trial
completion rate and accuracy.

11

Data Analysis
Triazolam effects were analyzed using repeated-measures ANOVA with triazolam
dose, menstrual cycle phase and time as factors. Interactions were evaluated using
simple-effects analyses.
RESULTS
Drug Discrimination Task
Figure 1.1 presents mean drug-appropriate responding as a function of triazolam
dose administration during control and test sessions. During the final 5 control sessions,
which occurred at different menstrual cycle phases across subjects, drug-appropriate
responding emerged only after the active dose of triazolam was administered [dose by
time interaction: F(4, 24) = 14.78, p < .001], and greater than 80% responding occurred
reliably on the drug-appropriate option for all subjects beginning at 90 minutes post
dose. During the test phase, active drug-appropriate responding varied as a function of
menstrual cycle phase [dose x phase interaction: F(12, 72) = 2.13, p = .025], with simple
effects analysis indicating significant cycle phase effects occurring at the 0.12 mg/70 kg
test dose [F(9, 27) = 7.90, p < .001]. During the early follicular phase, three of seven
subjects identified placebo as triazolam, resulting in intermediate levels of responding
when averaged across all subjects, but responding was not significantly different from
that occurring during the mid-luteal phase at this dose. The 0.06 mg/70 kg dose was
identified as placebo during both cycle phases. The 0.12 mg/70 kg test dose was
identified as triazolam-like during the mid-luteal phase, whereas during the early
follicular phase, responding was comparable to that observed following placebo
administration.

The active training dose of triazolam (0.25 mg/70 kg) engendered

triazolam-appropriate responding during both menstrual cycle phases.
Adjective Rating Scale
A dose by menstrual cycle phase interaction was detected on the Stimulant
subscale of the ARS (p ≤ .05), with ratings at the 0.06 mg/70 kg dose showing greater
decreases during the mid-luteal phase relative to the early follicular phase (simple
effects: p ≤ .05).
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Other Measures
Consistent with previous studies (e.g., Rush et al., 2000; 1999; Stoops et al.,
2005), triazolam engendered prototypical sedative effects on many self-report,
performance, and cardiovascular measures (Table 1.2).

Baseline cardiovascular

measures varied across cycle phases (e.g., Ounis-Skali et al., 2006), but triazolam
effects were independent of cycle phase across all other measures.
Additional data (means and standard errors for each measure collected) are
available in Appendix A.
DISCUSSION
The results of this study clearly demonstrate that triazolam functioned as a
discriminative stimulus in healthy women and that sensitivity to the discriminative
stimulus effects of triazolam was influenced by menstrual cycle phase. The
discriminative stimulus effects of the 0.12 mg/70 kg test dose were enhanced during the
mid-luteal phase, compared to the early follicular phase, of the menstrual cycle. These
results, along with a growing body of literature, support the hypothesis that progesterone
modulates the behavioral effects of GABAergic drugs (e.g., Grant et al., 1997, Green et
al., 1999; Kroboth et al., 1985; McAuley et al., 1995).
Menstrual cycle phase effects were detected with drug discrimination and with
the stimulant subscale of the ARS. Previous research using drug discrimination with
nonhuman primates showed enhanced sensitivity to alcohol effects during the mid-luteal
phase (Grant et al., 1997, Green et al., 1999); however, self-report measures of sedative
drug effects have not typically changed across menstrual cycle phases in clinical studies
(e.g., Holdstock & de Wit, 2000; Rukstalis & de Wit, 1999). These data suggest that drug
discrimination may be more sensitive to menstrual cycle phase modulation of sedative
drug effects than self-report measures alone.

It is has been suggested that drug

discrimination may be more sensitive to drug action at the receptor level, such that drugs
with similar pharmacological profiles share similar discriminative effects, while subjective
effect measures may be more likely to reflect interoceptive cues engendered by nonpharmacological states (Kelly et al., 2003). As drug discrimination establishes consistent
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responding in the presence of a drug effects, it provides formalized pharmacological
training for each participant, whereas subjective measures rely on participants’ verbal
history to identify interoceptive drug effects. The discordance between the discriminative
stimulus and subjective effects of drugs has been reported across several drug classes
(Preston & Bigelow, 1991; Chait et al., 1986; Kelly et al., 2003) and may be in part
influenced by verbal conditioning history, contingencies associated with responding, or
training conditions.
During control sessions, which were scheduled without regard to menstrual cycle
phase, the 0 mg/70 kg dose engendered consistent responding on the non-drug option.
Surprisingly, during the early follicular phase of test sessions, placebo engendered
triazolam-appropriate responding in three of seven participants. The potential influence
of several factors was examined, including the number of days post menses of testing,
prior drug use history, rate of acquisition of the triazolam discrimination, and menstrual
cycle phase during control sessions, but none served as a reliable predictor of placebo
responding during the early follicular phase.
There were a few notable limitations to the current study. First, although cycle
phases were determined using the onset of menses and objective measures of ovulation
among women with regular menstrual cycles, plasma hormone levels were not
measured. The correlations between serum levels of estradiol and progesterone and
drug response have been demonstrated (White et al, 2002; Justice & de Wit, 2000; de
Wit & Rukstalis, 1997). Second, the Sampling and Control Phases of the discrimination
training were conducted without regard to menstrual cycle phase. It is possible that
varied hormone levels during sampling and control phases may have influenced either
rate of acquisition of the discrimination or results obtained during the test phase.
However, we were unable to identify any factors, related to cycle phase or otherwise,
that were associated with individual differences in the rate of acquisition of the
discrimination.

Furthermore, the proportion of participants acquiring the drug

discrimination (7 of 12) is comparable to that in other triazolam drug discrimination
studies (Vansickle & Rush, 2006; Rush et al., 2003; Rush et al., 2000; Kamien et al.,
1997). Third, although a within-subject design was employed, the sample size was
modest, and the sensitivity of self-report and other measures to cycle phase effects
might have been established with a larger sample.
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Although this study provided clear evidence that the effects of triazolam vary
across the menstrual cycle, the relative role of progesterone in this effect is unclear.
During the early follicular phase, both progesterone and estrogen are at nadir levels.
During the mid luteal phase, peak levels of progesterone emerge; however, estrogen
levels are elevated as well. Despite the well-documented evidence of progesterone and
its metabolites modulating GABAA activity through a receptor-based mechanism, this
study cannot provide conclusive evidence that the interaction observed was exclusively
mediated by elevated levels of endogenous progesterone. Therefore, follow-up studies
were conducted to isolate and directly manipulate the effects of progesterone to
determine if acute progesterone administration modulates the effects of triazolam.
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Table 1.1. Demographic data from participants who acquired the triazolam
discrimination and those who were unable to acquire the discrimination.
Age
Weight (kg)
Caffeine (mg/day)
Alcohol (drinks/week)
Nicotine (cigarettes/day)
Other drug use
Beck
MAST
ADHD

Discriminators (n=7)
29.86
59.71
105.58
0.53
10 (n=1)
None reported
4.29
1.29
2.57
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Non-Discriminators (n =5)
20.20
70.00
29.33
2.30
0.17 (n=1)
None reported
2.00
3.40
3.40

Table 1.2. Significant F-values of selected measures for which a significant main
effect or interaction was obtained. No Triazolam x Cycle x Time interactions
were detected.
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FIGURE 1.1. Average triazolam-appropriate responding as a function of triazolam dose
and menstrual cycle phase from assessments occurring between 90 and 150
minutes post dose. The left panel displays responding during the Control Phase,
during which training doses were administered. Data points represent means (±
SEM denoted by the error bars) of seven subjects. The asterisk indicates a
significant difference (p ≤ .05) across cycle phase.
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CHAPTER 3
STUDY 2: Separate and combined effects of progesterone and triazolam in
healthy, premenopausal women
INTRODUCTION
Gender differences in drug use and abuse are notable, with greater numbers of
men reporting non-medical use of drugs than women (SAMHSA, 2009). However, the
relative

risk

of

developing

dependence

on

sedative-hypnotic

drugs

(e.g.,

benzodiazepines) appears to be greater for women than men. After initiating sedativehypnotic drug use, women are significantly more likely to develop problematic use
patterns relative to their male counterparts, such that women may be nearly twice as
likely to develop dependence on these compounds (Kandel et al., 1998; Anthony et al.,
1994). In addition, women are prescribed sedative-hypnotic compounds at higher rates
than men (Nomura et al., 2006; Howes et al., 1996; van der Waals et al., 1993;
Wysowski & Baum, 1991), take the medications longer once prescribed (Geiselmann &
Linden, 1991), and are more likely to use the medications for non-medical purposes
(Simoni-Wastila et al., 2004).
Biological factors, including ovarian hormones, and more specifically the
neurosteroid progesterone and its metabolites, might contribute to these gender
differences in sedative-hypnotic drug abuse. Neurosteroids (e.g., progesterone,
estradiol) are abundantly present in premenopausal women, with plasma concentrations
varying as a function of menstrual cycle phase. Research from a variety of sources
indicates that neurosteroids modulate receptor systems and alter drug effects (McAuley
et al., 1995; White et al., 2002; Justice et al., 1999; Lynch et al., 2002; Lile et al., 2007).
Progesterone

and

its

primary

and

derivative

metabolites,

allopregnanolone,

pregnanolone, and TH-DOC, modulate neurotransmitter activity via genomic and nongenomic mechanisms. The non-genomic effects of these neurosteroids include direct
activation of neuronal membrane-bound receptors and the rapid modulation of several
neurotransmitter systems including GABA, dopamine, opiate, glutamate and nicotinic
acetylcholine systems (Pluchino et al., 2006; Lena et al., 1993). The best-characterized
and perhaps most influential of progesterone’s effects are those at the GABA A receptor
complex. Sedative-hypnotic drugs such as the benzodiazepines also produce their
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effects, in large part, via modulation of GABA A receptors.

Allopregnanolone,

pregnanolone and TH-DOC are ligands at extracellular, steroid-specific recognition sites
on GABAA receptors, with affinities that are comparable to those of many
benzodiazepines (Paul & Purdy, 1992). In addition, these neurosteroids dosedependently increase the effects of benzodiazepines on GABA-induced Cl- currents,
indicating

that

there

is

a

non-genomic,

receptor-level

interaction

between

benzodiazepines and neurosteroids (Paul & Purdy, 1992; Bertz et al., 1995). The
behavioral effects of these neurosteroids also overlap with those engendered by
benzodiazepines and include sedation, memory impairment, anxiolysis, depression,
stress reduction and anti-seizure effects (Pisu & Serra, 2004; Rhodes et al., 2004;
Rupprecht, 2003; Schumacher et al., 1989; Schumacher & Robert, 2002).
Because progesterone and its metabolites have a direct action at GABA receptor
sites, it is hypothesized that progesterone may potentiate the behavioral effects of
GABAergic drugs.

Preclinical studies have demonstrated that the discriminative

stimulus effects of ethanol are sensitive to menstrual cycle phase, such that the ethanol
generalization curve is shifted to the left during the mid-luteal phase of the menstrual
cycle when progesterone levels surge (Grant et al., 1997, Green et al., 1999). Similar
effects were observed in healthy, pre-menopausal women in Study 1, such that the
discriminative stimulus effects of triazolam were potentiated during the mid-luteal phase
relative to the early follicular phase. Other clinical research examining GABAergic drug
effects (i.e., triazolam and ethanol) across the menstrual cycle have found little or no
evidence for cycle modulation of drug effects (Holdstock & de Wit, 2000; Rukstalis & de
Wit, 1999).
Interactions between neurosteroids and benzodiazepines may be more apparent
when levels of neurosteroids are directly manipulated. Examining drug effects across
the menstrual cycle does not allow for a direct assessment of the effects of progesterone
because progesterone level increases during the mid-luteal phase coincide with estradiol
level increases.

An alternative strategy is to assess the effects of exogenously

administered progesterone during the early follicular phase when both progesterone and
estradiol levels are at nadir levels. When administered as a pre-treatment, exogenous
oral

micronized

progesterone

enhanced

the

sedative,

memory-impairing

and

performance effects induced by intravenous triazolam in post-menopausal women
(McAuley et al., 1995). Those results support the use of this methodology to more
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directly examine interactions between neurosteroids and drug effects. However, there do
not appear to be any studies that used progesterone-only pretreatments to evaluate
potential interactions between neurosteroids and sedative-hypnotic drugs in healthy premenopausal women, who might be at increased risk for developing benzodiazepine-use
disorders. Thus, further study of the effects of GABAergic drugs following controlled
administration of progesterone is warranted and should not only provide additional useful
information regarding progesterone modulation of the GABA-mediated behavioral effects
of drugs, but also help elucidate gender-specific sensitivity to the effects of
benzodiazepines. The purpose of the present study is to determine the independent and
combined subjective and psychomotor effects of progesterone and triazolam in healthy
adult premenopausal women.
METHOD
Participants
This study used methods similar to those of Study 1 and participant recruitment
procedures, medical screening protocol and exclusion criteria were the same across
studies. Eligibility criteria for this study was slightly different and included a minimum of
18 years of age, reports of occasional sedative drug use (e.g., alcohol), and use of an
oral, hormone-based contraceptive that included a 7 consecutive-day placebo phase.
Sixteen participants were enrolled in the study.

Five participants did not

complete the study for reasons unrelated to the protocol and their data are not included
in the analyses.

Eleven women (10 Caucasian, 1 African American) completed the

study. The participants ranged in age from 21 to 26 years (median = 22 years) and in
weight from 51 to 72.4 kilograms (median = 63 kg; BMI range= 19.2 to 26.3, median =
22.2). All participants were non-smokers. Alcohol use ranged from less than 1 to 7.5
alcohol drinks per week (median = 3) and caffeine use ranged from 0 to 185 mg of
caffeine per day (median = 80 mg).

One participant reported nonmedical use of a

prescription stimulant medication (i.e., Adderall) on two occasions in the month prior to
study participation. Participants reported no additional psychoactive drug use in the
month prior to study participation and no drug use was detected during the study with
daily urinalysis testing. Participants were compensated for their participation.
Design
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A double-blind, placebo-controlled, randomized design was used to assess the
effects of three within-subject variables, progesterone dose (0, 100 and 200 mg),
triazolam dose (0.00, 0.12 and 0.25 mg/70 kg), and time (30, 60, 90, 120 and minutes
after triazolam administration, which correspond to 75, 105, 135, 165, 195 after
progesterone administration), on the subjective, performance and cardiovascular effects
of triazolam during the early follicular phase of the menstrual cycle (e.g., the placebo
phase of the oral birth control regimen) when estrogen and progesterone levels are at
their nadir.
Drugs
Doses of progesterone and triazolam were prepared by the University of
Kentucky Investigational Pharmacy. Progesterone (0, 100, 200 mg; Prometrium) and
triazolam (0.00, 0.12 and 0.25 mg/70 kg) were prepared in size 00 and 0 distinct opaque
capsules, respectively, each with cornstarch filler.

Placebo capsules contained only

cornstarch filler. Both progesterone and triazolam doses were delivered orally.
Schedule
Participants completed one training session prior to the experimental sessions to
acquaint them with the study procedures and to establish consistent and accurate
performance on computerized behavioral tasks. This practice session was conducted
irrespective of menstrual cycle phase but within one week of the initiation of the
experimental sessions. The subsequent nine experimental sessions were conducted
during the participant’s placebo phase of their oral birth control regimen (e.g., early
follicular phase). Each permutation of progesterone and triazolam doses was tested
once in random order. Each experimental session was 6 hours in length. Participants
completed the study across 2-4 months time, with each session occurring at
approximately the same time of day across the study.
Screening and laboratory check in procedures (i.e., drug testing, field sobriety
test) were identical to those used in Study 1 and were consistent across studies.
Thirty minutes after progesterone administration, participants consumed a
moderate-fat snack to enhance progesterone absorption (Simon et al., 1993; Stanczyk,
1999). Triazolam was administered 15 minutes after snack delivery. Assessments were
repeated in 30-minute intervals for 3 hours after triazolam administration.
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Each

assessment consisted of Visual Analog (VAS) and Adjective Rating (ARS) Scales,
Addiction Research Center Inventory (ARCI), Profile of Mood States (POMS), Digit
Symbol Substitution Task (DSST), Balloon Analog Risk Task (BART) and heart rate and
blood pressure measurement (Sentry II, NBS Medical, Costa Mesa, CA). Only measures
that are different form those used in Study 1 are described below.
Assessment Tasks
VAS
Similar to the version used in Study 1, the scale presented in the current study
included 32 items, including: Stimulated, Stressed, Sedated, Anxious, Nervous, LightHeaded, Sleepy, Sick to Stomach, Shaky, Jittery, Depressed, High, Euphoric, Active,
Alert, Energetic, Drug Effect, Good Drug Effect, Bad Drug Effect, Performance Impaired,
Performance Improved, Like Drug, and Pay for Drug.
ARCI
The 49-item short form of the true-false inventory (Martin et al., 1971) yielded
information on five dimensions: Lysergic Acid Diethylamide (LSD) scale, Amphetamine
(A) Scale, Benzedrine-Group (BG) Scale, Morphine-Benzedrine Group (MBG) Scale and
the Pentobarbital, Chlorapromazine, Alcohol Group (PCAG) Scale.
ARS
The Adjective Rating Scale consists of 32 items and contains two subscales:
Sedative and Stimulant (Oliveto et al., 1992). In the present study, only the 16 items
from the Sedative subscale were presented.

Participants rated each item using a

numeric keypad to select one of five options: “Not at All”, “A Little Bit”, “Moderately”,
“Quite A Bit” and “Extremely” (scored numerically from 0 to 4, respectively; maximum
score =64).
BART
Participants were presented with 20 individual balloons in succession on a
computer screen, as adapted from Lejuez et al., 2002. Participants clicked a mouse to
inflate each balloon. Each inflation increased the balloon earnings counter by $0.01 and
increased the probability of the next inflation to pop the balloon. Each balloon would pop
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after a random, unpredictable number of inflations. Participants could collect their
balloon earnings prior to a balloon popping by clicking on a “Collect Money” option.
However, if a balloon popped, earnings from the balloon were permanently lost.
Earnings from each task presentation were recorded and participants were given their
task earnings from a randomly chosen assessment at the end of the session. The
dependent measures were number of inflation responses per un-popped balloons, and
number of balloons popped.
Data Analysis
Drug

effects

were

analyzed

using

repeated-measures

ANCOVA

with

progesterone dose, triazolam dose and time as factors and baseline assessment prior to
drug administration serving as a covariate. Significant interactions were evaluated using
simple-effects analyses. Because baseline measures were used as covariates, drug
effects were identified by a main effect of dose or a dose by time interaction, depending
on the time course of the drug effect.

Similarly, drug interactions were apparent as

either a drug by drug interaction, or a drug by drug by time interaction, again depending
on the time course of the interaction.
RESULTS
Independent of progesterone, triazolam produced prototypical sedative-like
effects on multiple measures including VAS Sleepy, ARS Sedated and POMS Fatigue
(Table 2.1). Figure 2.1 presents VAS ratings of Drug Effect (top row), VAS ratings of
Sedated (middle row) and ARCI PCAG Scale ratings (bottom row) as exemplars.
Triazolam increased subjective ratings on each scale, as evidenced by a main effect of
triazolam and triazolam by time interaction (Table 2.1).

Based on simple effects

analyses, triazolam effects occurred at the high dose of triazolam (0.25 mg/70 kg) 90
through 150 minutes after dose administration on VAS Drug Effect (Figure 2.1, open
squares, panels A through C) and ARCI PCAG scale (open squares, panels D through
F), and occurred 120 through 150 minutes on the VAS Sedated Scale (open squares,
panels G through I).
Both doses of progesterone also produced sedative-like effects on a profile of
measures similar to those of triazolam (Table 2.1). Figure 2.1 (left column) displays the
time course of progesterone alone on VAS Drug Effect (panel A), VAS Sedated (panel
D), and ARCI PCAG scale (panel G), with peak effects of progesterone in combination
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with placebo triazolam occurring 75 through 105 minutes after progesterone
administration (i.e., 30 through 60 minutes post triazolam administration).
A significant interaction between progesterone and triazolam was also detected
on the sedative-like measures of drug effect, including POMS Fatigue (Table 2.1).
Figure 2.1 (top row) displays the progesterone by triazolam interaction on ratings of VAS
Drug Effect.

Simple effects analysis indicated significant progesterone effects at all

doses of triazolam, with increases occurring at both active doses of progesterone in
combination with the moderate dose (0.12 mg/70 kg) of triazolam (panel B) and
increases occurring at 200 mg of progesterone in combination with the high dose (0.25
mg/70 kg) of triazolam (panel C) (p < .05). Compared to progesterone alone (panel A),
the combination of progesterone and triazolam extended the duration of and delayed
peak ratings of VAS Drug Effect (panels B and C). Significant interactions were not
detected on ratings of VAS Sedated and ARCI PCAG, but the profile of effects were
similar to those of VAS Drug Effect, with increases in occurring when either dose of
progesterone was combined with the moderate dose of triazolam (0.12 mg/70 kg)
(panels E and H) and when 200 mg was combined with the high dose of triazolam (0.25
mg/70 kg) (panels F and I), the peak effects were delayed. .
Separate and combined effects of progesterone and triazolam were also
observed on measures that have typically considered to be indirect measures of the
reinforcing and aversive effects of drugs. For example, independent of progesterone,
triazolam increased ratings of VAS Euphoric and High (Table 2.1). Figure 2.2 displays
ratings of VAS Good Drug Effect (top row), VAS Bad Drug Effect (middle row) and VAS
Pay for Drug (bottom row) as representative measures. Triazolam modified ratings on
each scale, as evidenced by a main effect of triazolam (Table 2.1). The high dose of
triazolam (0.25 mg/70 kg) increased ratings of VAS Good Drug Effect (Figure 2.2, open
squares, panels A through C) and VAS Bad Drug Effect (open squares, panels D through
F), and decreased ratings of VAS Pay For Drug (open squares, panels G through I), with
these effects occurring at 90 through 150 minutes after triazolam administration.
As evidenced by a main effect of progesterone (Table 2.1), progesterone alone
also increased ratings of VAS Good Drug Effect 75 through 105 minutes after
progesterone administration (Figure 2.2, panel A) and VAS Bad Drug Effect at 105 to
135 minutes (panel D). No main effect of progesterone was detected on VAS Pay for
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Drug (panel G).

A significant interaction between progesterone and triazolam was detected on
each measure presented in Figure 2.2. Simple effects analyses of ratings of VAS Good
Drug Effect indicated that increases were observed when 100 mg of progesterone was
combined with the moderate dose of triazolam (Figure 2.2, panel B) and increases also
occurred when 200 mg of progesterone was combined with the high dose of triazolam
(panel C) (p <.05). Simple effect analyses of ratings of VAS Bad Drug Effect indicated
that increases occurred when either dose of progesterone was combined with the
moderate dose of triazolam (panel E) and when 200 mg of progesterone was combined
with high dose of triazolam (panel F) (p < .05). Simple effects analyses of ratings of VAS
Pay for Drug revealed an interaction primarily related to a small effect of progesterone at
placebo triazolam (panel G); however increased effects were also observed when 200
mg of progesterone was combined with the high dose of triazolam (Graph F) (p < .05).
Similar to the trends observed on measures of sedation (Figure 2.1), the combination of
progesterone and triazolam delayed the peak effects, compared to the effects of
progesterone alone.
Separate and combined effects of progesterone and triazolam were also
observed on measures of psychomotor task performance as well as self-evaluations of
performance acuity (Table 2.1). Figure 2.3 presents DSST measures of Total Trials
Completed (top row), and VAS ratings of Performance Impaired (middle row) and
Performance Improved (bottom row).

Main effects of triazolam or a triazolam by time

interaction were observed on each measure (p < .05). Simple effects analyses indicated
that triazolam effects on both DSST Total Trials (Figure 2.3, open squares, panels A
through C) and VAS Performance Impaired (open squares, panels D through F)
occurred at highest dose of triazolam (0.25 mg/70 kg) 90 through 120 minutes after
triazolam administration (p < .05). No triazolam by time interaction was detected on VAS
Performance Improved, but the time course was similar to other measures of
performance, with peak effects occurring 90 and 120 minutes post-dose.
A main effect of progesterone was observed on VAS Performance Impaired
(Table 2.1), with progesterone increasing ratings early in the session (Figure 2.3, panel
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D). A main effect of progesterone was also detected on DSST Total Trials (Table 2.1);
however minimal effects of progesterone were observed in combination with placebo
triazolam (panel A).
A significant interaction between progesterone and triazolam was also detected
on each of the measures in Figure 2.3. Simple effects analyses of DSST Total Trials
indicated that 200 mg progesterone combined with 0.12 mg/70 kg triazolam significantly
decreased trial completion (Figure 2.3, panel B) and on associated measures, such as
number of correct trials on the DSST (p < .05).

Simple effect analyses indicated

increases in VAS Performance Impaired ratings at both active dose of progesterone
combined with 0.12 mg/70 kg triazolam (panel E) and by 200 mg combined with 0.25
mg/70 kg (panel F) (p < .05). Simple effects analyses of VAS Performance Improved
indicated ratings were increased by the combination of 100 mg of progesterone and the
moderate dose of triazolam (panel H) and by 200 mg combined with the high dose of
triazolam, although the magnitude of the effect was small (panel I). Similar to other
measures (Figure 2.1 and 2.2), progesterone administration delayed the time to the peak
effects as triazolam dose increased.
Significant main effects of both progesterone and triazolam, as well as a
significant interaction between progesterone and triazolam, were observed on number of
responses per un-popped balloon on the BART (Table 2.1). Follow-up testing of the
progesterone by triazolam interaction indicated an effect of progesterone at each dose of
triazolam and an effect of triazolam only at 100 mg dose of progesterone (p < .05).
Examination of these data indicated significant variability in the number of responses per
balloon occurring during baseline sessions, with small magnitude increases across time
following placebo progesterone administration and a small magnitude decrease following
either 100 or 200 mg progesterone. This effect was particularly evident at the 0.12
mg/70 kg dose of triazolam. No differences in number of responses per balloon were
observed at any assessment, indicating that progesterone and triazolam effects on this
task are related to variability in performance as opposed to any reliable
neuropharmacological effects of either compound.
Separate and combined effects of progesterone and triazolam were also
observed on cardiovascular measures (Table 2.1). Follow up analyses indicated small
magnitude increases in each cardiovascular measure across time, but no systematic
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changes due to administration of either drug were observed at any assessment. These
trends indicate that statistical significance was related to variability at baseline
measurements as well as across assessments and not systematically related to
pharmacological modulation of cardiovascular measures.
Additional data (means and standard errors for each measure collected) are
available in Appendix B.
DISCUSSION
The present study used subjective, performance and cardiovascular measures to
evaluate the effects of exogenous progesterone, alone and in combination with
triazolam, in healthy, pre-menopausal women. The results of this study demonstrated
that both progesterone and triazolam, alone, produced sedative-like effects, and that
their effects in combination were greater than those of either compound in isolation. In
addition, the drug combination also shifted the time course of triazolam effects, with
peak effects occurring later in the session.
Triazolam, when administered alone, engendered prototypical subjective, performance
and cardiovascular effects, most consistently at the highest dose (0.25 mg/70 kg). Peak
behavioral effects of 0.25 mg/70 kg triazolam occurred between 1.5 and 2.5 hours after
dose administration, which is consistent with previous reports (Rush et al., 2003;
Simpson & Rush, 2002). Progesterone alone also produced sedative-like effects on a
variety of subjective effect measures at both doses, with peak behavioral effects
occurring between 1.25 and 1.75 hours after progesterone administration (30 and 60
minutes post triazolam administration). The magnitude and time course of these effects
were somewhat different than have previously been reported. Sedative-like effects of
progesterone are typically limited to administration of higher oral doses than were used
in this study, or to routes of administration with greater bioavailablity (i.e., intramuscular
administration) (Freeman et al., 1993; Soderpalm et al., 2004; de Wit et al., 2001). In
addition, peak effects of oral progesterone have previously been reported to occur
between 2 and 2.5 hours after drug administration (Sofuoglu, et al., 2001, 2002;
Chakmakjian & Zachariah, 1987). The most likely factor contributing to the more rapid
onset and increased magnitude of sedative-like effects in the present study was the
administration of a moderate-fat snack thirty minutes after progesterone administration,
as the administration of a moderate-fat meal has been reported to increase
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progesterone bioavailability (Simon et al., 1993; Stanczyk, 1999).

However, other

factors, such as participant characteristics (i.e., participants in this study were light
drinkers, had limited or no previous benzodiazepine exposure, and were taking oral birth
control), could also have contributed to the pharmacodynamic effects observed in the
present study.
The combined effect of progesterone and triazolam resulted in enhanced
subjective, performance and cardiovascular effects, as compared to those of triazolam
or progesterone in isolation. The combination of progesterone and triazolam also shifted
the time course of peak progesterone effects. When administered alone, progesterone
effects were limited to initial assessments (1.25 to 1.75 hours after progesterone
administration). However, when progesterone was combined with either active dose of
triazolam, the peak effects were shifted to time points in the latter portion of the session
(135 through 195 minutes after progesterone administration, or 90 through 150 minutes
after triazolam administration). Generally, both doses of progesterone combined with the
moderate dose of triazolam (0.12 mg/70 kg) produced an enhanced effect, while only the
200 mg dose of progesterone produced increased effects at the high dose of triazolam
(0.25 mg/70 kg). In addition, peak effects of progesterone in combination with the 0.12
and 0.25 mg/70 kg dose of triazolam occurred at times in which progesterone, alone,
had minimal subjective, performance or cardiovascular effects.
The enhanced magnitude of triazolam effects occurring at times in which
progesterone, alone, had minimal effects and the shifted time course of progesterone
effects may be associated with circulating levels of the neuroactive progesterone
metabolites allopregnanolone and TH-DOC which are GABAA ligands and can produce
behavioral effects similar to alcohol and benzodiazepines (Lambert et al., 1995, 2009;
Grant et al., 2008). Although TH-DOC and pregnanolone levels rise after progesterone
administration, the clinical time course of these hormone derivatives have not been
established.

After

oral

progesterone

administration,

peak

progesterone

and

allopregnanolone levels occur at 2 hours, with levels remaining elevated above baseline
for a total of 5 and 8 hours, respectively (Andréen et al., 2006; Nahoul et al., 1993). In
the absence of blood levels of progesterone and its metabolites, the relative impact of
each neurosteroid is not clear. However, the time course of these hormones may help
inform the basis of the enhanced effect of the combination of progesterone and triazolam
during times when progesterone alone engendered minimal subjective or performance
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effects (i.e., 135 through 195 minutes after progesterone administration).
Although progesterone activity at GABAA receptor complex is the most wellcharacterized

effect,

other

neurotransmitter

progesterone is combined with triazolam.

systems

may

be

involved

when

Progesterone and its metabolites may

engender some effects via modulation of other neurotransmitter systems, as these
neurosteroids have been shown to rapidly modulate dopamine, serotonin, opiate,
glutamate and nicotinic acetylcholine systems (Pluchino et al., 2006; Lena et al., 1993).
Further research is necessary to determine the specificity of neurosteroid modulation of
benzodiazepines.
Overall, the combined effect of progesterone and triazolam yielded rather
consistent effects on a variety of sedative-like measures.

However, seemingly

incongruent effects on subjective measures of drug effect and performance ability
emerged in this study.
similarly,

ratings

of

VAS ratings of Good Drug Effect and Bad Drug Effect and
Performance

Impaired

and

Performance

Improved

were

simultaneously increased after administration of the combination of progesterone and
both active doses of triazolam. Many drugs of abuse engender simultaneous positive
and negative drug effects, and it has been proposed that the balance between these
opposing effects may determine how readily a drug is self-administered (Foltin and
Fischman, 1991). Subjective effect ratings of performance ability and psychomotor task
performance were also somewhat disparate. When progesterone was administered in
isolation, ratings of VAS Performance Impaired increased while DSST Total Trials, an
objective measure of performance, was not substantially affected. Triazolam impaired
DSST task performance, while simultaneously increasing ratings of both performance
impairment and improvement. Inconsistencies between self-ratings of performance and
objective measures of behavior have been previously reported (Marczinski et al, 2008;
Brumback et al., 2007; Marczinski & Fillmore, 2006; Roache & Griffiths, 1985), although
it is not clear whether changes in dimensions of performance that were not measured in
the present study (e.g., reaction time, response inhibition, coordination) could have
influenced participant’s ratings of improved performance.
BART performance was not sensitive to the effects of triazolam or progesterone,
which is consistent with previous reports that have examined the acute effects of dose
ranges of other GABAergic drugs, such as diazepam (Reynolds et al., 2004) and alcohol
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(Reynolds et al., 2006), suggesting that performance on this measure of impulsivity is
generally insensitive to the acute effects of GABAergic drugs in healthy participants.
Similarly, cardiovascular activity was minimally affected by the dose range of
progesterone and triazolam tested in the present study, which is also consistent with
previous studies reporting minimal effects of either progesterone or triazolam (at similar
doses) on cardiovascular activity (Sofuoglu et al., 2002, 2004; Haga et al., 2003;
Simpson & Rush, 2002).

The present study extends these previous results by

demonstrating that the combined effects of triazolam or progesterone also have
negligible effects on BART performance and cardiovascular activity.
Some limitations to the present study should be noted. In the current study, both
active doses of progesterone engendered some sedative-like effects in isolation, and
generally only the highest dose of triazolam produced statistically significant effects
compared to placebo. Future studies should examine progesterone and benzodiazepine
interactions with a wider range of benzodiazepine doses and include progesterone
doses that engender minimal measurable effects when administered in alone. Another
limitation to this study was the unexpected discordance of the onset of peak effects of
progesterone and triazolam, with peak progesterone effects occurring approximately 1
hour prior to the peak effects of triazolam. Although the study was designed to examine
concomitant peak effects, the separate peak of effects of each compound allowed for
interesting interactions to emerge.

Experimental sessions were conducted only during

the 7-day placebo phase of participants’ oral contraceptive regimen. Because the study
consisted of 9 sessions, it could not be completed during one week, which resulted in
some sessions being separated by several weeks. However, this design allowed for
sessions to occur when progesterone and estradiol were at nadir levels, permitting
controlled manipulation of progesterone levels. A similar design was used to assess
hormonal modulation of the discriminative stimulus effects of the stimulant drug damphetamine in women (Lile et al., 2007).

Separating sessions could also have

reduced the likelihood that tolerance or sensitization would occur.
These results, along with a growing body of literature, support the hypothesis that
progesterone modulates the behavioral effects of GABAergic drugs (e.g., Grant et al.,
1997; Green et al., 1999; Kroboth et al., 1985; McAuley et al., 1995). In addition, these
data suggest that progesterone may be one factor among many that contributes to the
gender differences observed in benzodiazepine misuse, whereby women are at an

31

elevated risk of developing dependence on benzodiazepine medications compared to
men. Taken together, these studies should inform potential strategies in gender-specific
prevention and treatment of sedative drug use.
Although an interaction between progesterone and triazolam was observed in
this study, this interaction occurred after the effects of progesterone had dissipated. It is
unclear if the magnitude of this interaction would be enhanced if simultaneous peak
effects were generated, or if the interaction was due to progesterone metabolites, which
emerge after the peak effects of progesterone.

To more thoroughly investigate the

mechanisms of this interaction, the final study will adjust the timing of progesterone and
triazolam administration so that simultaneous peak effects emerge. In addition, this
study will also complement the results of Studies 1 and 2 as it incorporates drug
discrimination methodology to more thoroughly assess the neuropharmacological effects
of progesterone, alone and combination with triazolam.
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Table 2.1. F-values of selected measures for which a significant main effect or
interaction was obtained.
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FIGURE 2.1. Mean ratings of VAS Drug Effect (top panel), VAS Sedated (middle panel)
and ARCI PCAG Scale (bottom panel) as a function of triazolam dose,
progesterone dose and time following triazolam/progesterone administration. Data
points represent means (±S.E.M. denoted by the error bars) of 11 participants.
Different y-axis scales are used across the three measures.
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Figure 2.2. Mean ratings of VAS Good Drug Effect (top panel), VAS Bad Drug Effect
(middle panel) and VAS Pay for Drug (bottom panel) as a function of triazolam
dose, progesterone dose and time following triazolam/progesterone administration.
Data points represent means (±S.E.M. denoted by the error bars) of 11
participants. Different y-axis scales are used across the three measures.
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Figure 2.3. Mean trials completed on DSST Total Trials (top panel), ratings of VAS
Performance Impaired (middle panel) and VAS Performance Improved (bottom
panel) as a function of triazolam dose, progesterone dose and time following
triazolam/progesterone administration. Data points represent means (±S.E.M.
denoted by the error bars) of 11 participants. Different y-axis scales are used
across the three measures.
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CHAPTER 4
STUDY 3: Progesterone modulation of the discriminative stimulus, subjective and
performance effects of triazolam in healthy, pre-menopausal women
INTRODUCTION
Neurosteroids (e.g., progesterone, allopregnanolone) are abundantly present in
premenopausal women, with plasma concentrations varying as a function of menstrual
cycle phase.

Both pre-clinical and clinical research indicates that neurosteroids

modulate receptor systems and alter drug effects (McAuley et al., 1995; White et al.,
2002; Justice et al., 1999; Lynch et al., 2002; Lile et al., 2007). Progesterone and its
metabolites, allopregnanolone, TH-DOC, and pregnanolone, have non-genomic effects
at binding sites on neuronal membrane-bound receptors and also modulate several
neurotransmitter systems including GABA, dopamine, opiate, glutamate and nicotinic
acetylcholine systems (Pluchino et al., 2006; Lena et al., 1993). In particular, both in
vitro and in vivo studies have shown evidence that progesterone and its metabolites
modulate activity at the GABAA receptor complex, with these neurosteroids acting as
ligands at extracellular, steroid-specific recognition sites on GABA A receptors, having
affinities that are comparable to those of many benzodiazepines (Paul & Purdy, 1992).
The

neuroactive

metabolites

also

dose-dependently

increase

the

effects

of

benzodiazepines on GABA-induced Cl- currents, indicating that there is a non-genomic,
receptor-level interaction between benzodiazepines and neurosteroids in vitro (Paul &
Purdy, 1992; Bertz et al., 1995).
Pre-clinical research has indicated that menstrual cycle phase modulates the
some of the effects of GABAergic drugs. The discriminative stimulus effects of ethanol
are enhanced during the mid-luteal phase, when endogenous progesterone levels are
elevated (Grant et al., 1997, Green et al., 1999).

Study 1 demonstrated cycle

modulation of benzodiazepine effects in pre-menopausal women, with potentiation of the
discriminative stimulus effects of triazolam occurring during the mid-luteal phase (relative
to the early follicular phase). However, there is little or no evidence for cycle modulation
of the subjective and performance effects of GABAergic drug effects (i.e., triazolam,
ethanol) in pre-menopausal women (Holdstock & de Wit, 2000; Rukstalis & de Wit,
1999). One potential reason for the inconsistent clinical results could be due to the
sensitivity of drug discrimination methodology, as cycle modulation of the discriminative
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stimulus effects of drugs may be more sensitive to neuropharmacological manipulations
than subjective or performance measures (Kelly et al., 2003).
Examining drug effects across the cycle provides information about how the
endogenous hormonal milieu modulates drug effects, but does not provide a direct
measure of the relative effect of a particular hormone, due to several hormones
simultaneously fluctuating throughout the cycle.

For example, during the mid-luteal

phase, progesterone levels increase, but estradiol levels are elevated as well, making it
difficult to discern the effect of progesterone alone. To determine the independent effect
of progesterone and its primary metabolites, the effects of GABAergic drugs have also
been examined after exogenous progesterone administration. Administration of oral
micronized progesterone enhanced the sedative, memory and performance effects of
intravenous triazolam in post-menopausal women (McAuley et al., 1995). In addition,
the results of Study 2 indicated that oral micronized progesterone enhanced the
subjective and performance effects of oral triazolam in healthy, premenopausal women
during the early follicular phase, when endogenous progesterone and estrogen are at
nadir levels. These studies provide evidence that acute administration of progesterone
enhances some behavioral effects of benzodiazepines.

However, in both of these

studies, the onset and peak effects of progesterone occurred prior to the peak effects of
triazolam and interactions between progesterone and triazolam were detected after peak
progesterone effects had occurred. The asynchronous time courses for progesterone
and triazolam suggest that their interactions might have be underestimated, or driven
predominantly by neuroactive progesterone metabolites, specifically allopregnanolone,
which remains elevated several hours after oral progesterone levels peak.
The purpose of the present study was to determine the independent and
combined discriminative stimulus, subjective and psychomotor effects of progesterone
and triazolam in healthy adult pre-menopausal women using a dosing schedule that
should allow for peak drug and hormone effects to occur concurrently. This arrangement
allows for a close examination of the potential interaction between the two compounds
and provides information regarding the hormonal constituents that may drive the
interaction (i.e., the parent hormone progesterone vs. the progesterone metabolites that
occur several hours after progesterone levels peak). Drug discrimination methodology
was chosen to more precisely examine the neuropharmacological effects of
progesterone, alone and combination with triazolam, as drug discrimination has been
shown to be an effective tool in examining pharmacological changes mediated by
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receptor-based interactions (Colpaert, 1999; Kelly et al., 2003).

METHOD
Participants
Recruiting procedures, medical screening protocols and inclusion/exclusion
criteria were identical to those used in Study 2.
Fourteen participants were enrolled in the study. Three participants withdrew
from the study for reasons unrelated to the study protocol, two were discontinued from
the study because they did not acquire the drug discrimination; data from these five
participants were not included in the data analyses. Nine participants (8 Caucasian, 1
African American) completed the study. The participants ranged in age from 18 to 30
years (median = 22 years) and in weight from 55 to 93 kilograms (median = 65.95 kg;
BMI range = 21 to 31, median = 22.1). All participants were non-smokers. Alcohol use
ranged from less than 1 to 8 alcohol drinks per week (median = 4) and caffeine use
ranged from 0 to 200 mg of caffeine per day (median = 80 mg). Participants reported no
psychoactive drug use in the month prior to study participation and no drug use was
detected during the study with daily urinalysis testing. Urine screens for pregnancy were
also negative throughout participation. Participants were compensated for their
participation.
Design
A double-blind, placebo-controlled, randomized design was used to assess the
effects of three within-subject variables: progesterone dose (0 and 100mg), triazolam
dose (training doses: 0.00 and 0.25 mg/70 kg, test doses: 0.06 and 0.12 mg/70 kg), and
time (assessments occurring prior to and 30, 60, 90, 120 and 150 minutes after dose
administration) on the discriminative stimulus and other behavioral effects of triazolam
during the early follicular phase of the menstrual cycle (i.e., placebo phase of the oral
birth control regimen), when estrogen and progesterone levels are at their nadir.
The results of Study 2 indicated that oral progesterone, when administered with a
moderate-fat snack, produced peak behavioral effects 75 to 105 minutes post-dose,
while oral triazolam effects occur 90 to 150 minutes post dose. In an effort to examine
the concurrent peak effects of these medications, progesterone and triazolam were
administered simultaneously.
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Drugs
Doses of progesterone and triazolam were prepared by the University of
Kentucky Investigational Pharmacy. Progesterone (0 and 100 mg; Prometrium ®) and
triazolam (0.00, 0.06, 0.12 and 0.25 mg/70 kg) were prepared in size 00 and 0 distinct
opaque capsules, respectively, each with cornstarch filler. Placebo capsules contained
only cornstarch filler. Both progesterone and triazolam doses were delivered orally.
Schedule
Participants completed one training session prior to the experimental sessions to
acquaint them to the study procedures and to establish consistent and accurate
performance on computerized behavioral tasks. This practice session was conducted
irrespective of menstrual cycle phase but within one week of the initiation of the
experimental sessions.
After a baseline assessment, progesterone and triazolam were administered
simultaneously.

Fifteen minutes after drug administration, participants consumed a

moderate-fat snack to enhance progesterone absorption (Simon et al., 1993; Stanczyk,
1999). Assessments were repeated at 30-minute intervals for 3 hours after drug
administration, and consisted of the Drug Discrimination Task (post-dose assessments
only), Visual Analog (VAS) and Adjective Rating Scales (ARS), Addiction Research
Center Inventory (ARCI), Profile of Mood States (POMS), Digit Symbol Substitution Task
(DSST), Balloon Analog Risk Task (BART) and heart rate and blood pressure
measurement (Sentry II, NBS Medical, Costa Mesa, CA). Only the drug discrimination
procedure will be described here, as it is somewhat different than the procedure used in
Study 1. The VAS, ARS, ARCI, POMS, DSST and BART are exactly the same as those
described in Study 2.
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Assessment Tasks
Drug discrimination task
During this task, two circles labeled with a letter code (e.g., “Drug A” and “Not Drug
A”) were displayed on the computer screen, each associated with a training dose
condition. Counters were displayed directly beneath the circles. A mouse controlled the
location of a cursor on the screen, and mouse button clicks with a cursor positioned on a
circle increased the counter associated with that circle according to a Fixed Interval (FI)
1-s schedule. The cursor could alternate across the circles without any consequence
under the FI schedule (i.e., no changeover delay). Up to 60 points could be allocated
across the two options.

The dependent variable for this task was the percent of

responding on the active drug-appropriate option.
The drug discrimination task in this study was slightly different than that used in
Study 1. This study established the discrimination using two options labeled ‘Drug’ and
‘Not Drug,’ rather than ‘Drug A’ and ‘Drug B.’ The Drug v. Not Drug procedure has been
reported to establish discrimination behavior that is more consistent with the
pharmacological activity and subjective effects of medications than other procedures
(e.g., the Drug A v. Drug B task used in study 1) (Preston & Bigelow, 2000; 1994;
Preston et al., 1992).
Sampling, control and testing phases were presented during the study. Sampling
and control phases were conducted without regard to menstrual cycle phase. The test
phase was scheduled to coincide with the early follicular phase of the menstrual cycle
(i.e., placebo phase of the oral birth control regimen), when endogenous levels of both
progesterone and estrogen are at nadir levels. Participants completed the Test Phase
across 2 to 4 consecutive menstrual cycle phases.
Sampling Phase
The sampling phase consisted of two experimental sessions. On each of the two
sessions, participants were informed that the medication she was receiving was ‘Drug A’
(0.25 mg/70 kg triazolam and 0 mg progesterone). A unique letter code (i.e., ‘Drug A’)
was used for each participant.

The following written instructions were available to

participants throughout this phase:
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"This is Drug A. During the next two days, you will receive Drug A. Pay close
attention to how Drug A makes you feel. In the future, you will not be told which dose you
have received and you will have to decide whether or not you received Drug A. During
the next two days your earnings from the Drug Identification Task will be based on how
many points you allocate to the Drug A option. Please do your best to allocate all the
points to the Drug A option."
Control Phase
The control phase was used to determine whether participants had acquired the
drug discrimination. Daily schedules during the control phase were identical to those
during the sampling phase, with the exception that the participants were blind to the
identity of the administered drug (i.e., Drug A, or Not Drug A) until the end of the session.
The training dose of triazolam (0.25 mg/70 kg, Drug A) or placebo (Not Drug A), and
placebo progesterone, were administered randomly under double-blind conditions, with
each triazolam dose presented at least twice, but the same dose was never
administered on more than three consecutive days. The criterion for acquisition of drug
discrimination was ≥ 80% of responses allocated to the drug-appropriate option during
the last assessment of the session (150 minutes post-dose) for five consecutive
sessions.

If the acquisition criterion was not met in 12 sessions, participants were

dismissed from the study. Participants who met criteria did so within 5 to 12 sessions.
Performance payment was contingent on discrimination responding, with 10 cents
earned for each correct response (i.e., points) allocated to the option associated with the
dose administered that day. The following written instructions were available to
participants:
“Today we will not tell you whether you received Drug A or Not Drug A. Instead, you
will have to decide whether you received Drug A or Not Drug A. If you think you received
Drug A, and in fact you did receive Drug A, you can earn extra money by responding on
the button labeled Drug A. If you do not think you received Drug A, and in fact you did
not receive Drug A, you can earn extra money by responding on the button labeled Not
Drug A. For example, if you feel that you did not receive any drug today, you should
respond on the button labeled Not Drug A. Similarly, if you think that you received a
drug, but it feels different than Drug A, you should respond on the button labeled Not
Drug A. You can change your drug identifications throughout today's session based on
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what you think at the time.
At the end of some sessions, the computer will present a screen that will tell you if
you received Drug A or Not Drug A. The number of points that you accumulated on the
correct button will then be converted to money and you will be told how much bonus
money you earned during today's session. At the end of some sessions, we may not be
able to tell you whether you received Drug A or Not Drug A. On the days that we cannot
tell whether you, your bonus earnings will be the average of the amount you earn on
days in which we can tell you that you received Drug A or Not Drug A.”
Test Phase
During the Test Phase, dose-response generalization functions were established
for triazolam (0.00, 0.06, 0.12, and 0.25 mg/70 kg) alone and in combination with
progesterone (0.00 and 100 mg). One permutation of progesterone (0 and 100 mg) and
triazolam (0.00, 0.06, 0.12, and 0.25 mg/70 kg) was administered during each
experimental session in random order, for a total of 8 sessions. On days that participants
received a training dose (i.e., 0.00 or 0.25 mg/70 kg oral triazolam with 0 mg sublingual
progesterone), participants received feedback regarding the accuracy of their
performance at the end of the session and payment was contingent upon accuracy (as
in the Control Phase). The instructions presented during the Control Phase were also
available during Test Phase sessions.
Data Analysis
Drug effects were analyzed using repeated-measures ANOVA with triazolam
dose, progesterone dose and time as factors. Interactions were evaluated using simpleeffects analyses.
RESULTS
Drug Discrimination
Figure 3.1 presents mean drug-appropriate responding as a function of triazolam
and progesterone dose during control and test sessions.

During control sessions,

participants met the drug discrimination acquisition criterion in a mean of 7 sessions
(range of 5 to 12, median = 8). Across the final 5 control sessions, all participants
emitted approximately 0 % and 99% drug appropriate responding 150 minutes after
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placebo and active drug administration, respectively. During the test phase, training
dose conditions (0.00 and 0.25 mg/70 kg) engendered 11% and 100% triazolam-like
responding. The test doses (0.06 and 0.12 mg/70 kg) produced intermediate triazolamlike responding, approximately 30% and 50%, respectively.

This intermediate

responding was due to averaging data from participants identifying the dose as either
drug-like or non-drug-like (i.e., quantal responding by individual subjects). Progesterone
alone engendered 27% drug-like responding, resulting from two participants identifying
100 mg progesterone as drug-like. Progesterone in combination with triazolam did not
modify drug discrimination responding at any triazolam dose.
Subjective Effects
Triazolam alone produced prototypical sedative-like effects on multiple self-report
measures, including increases in ARS Sedation, VAS Sedated, Sleepy and Performance
Impaired, POMS Fatigue and ARCI PCAG Scale (Table 3.1). In addition, a main effect of
triazolam or an interaction of triazolam and time was also observed for VAS LightHeaded, High, Energetic and Drug Effect and POMS Vigor, and Arousal (Table 3.1).
Figure 3.2 presents VAS ratings of Sedated (top row), Performance Impaired (middle
row) and Drug Effect (bottom row) as exemplars. As illustrated in Figure 3.2, peak effects
of triazolam occurred 60 through 90 minutes after administration on each measure.
Independent of triazolam, progesterone also engendered sedative-like effects,
including VAS Sedated, Sleepy and Performance Impaired (Table 3.1). In addition, a
main effect of progesterone or an interaction of progesterone and time was also
observed for VAS ratings of Drug Effect and Good Drug Effect (Table 3.1). Peak effects
of progesterone also occurred 60 to 90 minutes after administration on each measure.
The combination of progesterone and triazolam engendered small magnitude
increases in subjective effects, compared to either dose alone (Figure 3.2). The effects
of progesterone on the response to triazolam appeared to be additive; that is, the
magnitude of the increase in subject ratings associated with dose combinations was not
greater than that of progesterone alone. In addition, progesterone delayed the time at
which peak effects occurred for the high dose of triazolam (0.25 mg/70 kg; 90 through
150 minutes).
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Performance Effects
Triazolam

produced

prototypical

sedative-like

effects

on

measures

of

psychomotor task performance, with a main effect of triazolam detected on DSST trial
rate and accuracy (Table 3.1). Independent of triazolam, progesterone decreased trial
accuracy (Table 3.1).

Similar to what was observed for the combined effects of

progesterone and triazolam on subjective effects, small magnitude additive effects were
apparent for trial accuracy.
No independent or combined effects of progesterone or triazolam were observed
on BART performance.
Cardiovascular Effects
Significant triazolam and progesterone effects were observed on diastolic blood
pressure (Table 3.1); however, these effects were small in magnitude (approximately 5
mm Hg) and limited to specific points in time.

It is unlikely that these changes

represented systematic drug effects or drug interactions.
Additional data (means and standard errors for each measure collected) are
available in Appendix C.
DISCUSSION
The present study used drug discrimination and subjective, performance and
cardiovascular measures to examine the effects of progesterone, alone and in
combination with triazolam in healthy, pre-menopausal women. Consistent with previous
studies, triazolam alone engendered a broad range of sedative-like effects in a doserelated manner, with peak effects occurring 60 to 90 minutes post dose (Greenblatt et
al., 2005; Rush et al., 2003; Simpson & Rush, 2002; Rush & Ali, 1999). Progesterone
alone produced small magnitude increases in sedative-like measures with a similar time
course. The combination of progesterone and triazolam engendered additive effects on
subjective and performance effects and delayed the time at which the peak effects of the
0.25 mg/70 kg dose of triazolam occurred. Triazolam functioned as a discriminative
stimulus, but progesterone did not consistently substitute for or modulate the
discriminative stimulus effects of triazolam
One aim of this study was to examine the effects of progesterone and triazolam
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under conditions in which the peak effects for the hormone and drug occurred at similar
times.

To accomplish this goal, progesterone and triazolam were administered

simultaneously, as Study 2 has indicated that peak effects emerge at similar times. This
approach was successful with peak effects of both progesterone and triazolam occurring
60 to 90 minutes post-dose. Worth mentioning is that self-reported and performance
effects of progesterone alone are not typically observed unless significantly higher oral
doses (600 to 1200 mg) or routes of administration with greater bioavailablity (i.e.,
intramuscular administration) are administered (Freeman et al., 1993; Soderpalm et al.,
2004; de Wit et al., 2001; van der Meer et al., 1982). These results replicate the results
of Study 2 in which doses of progesterone (100 and 200 mg PO) also increased ratings
of several sedative-like measures and engendered decreases in psychomotor task
performance. The effects of progesterone may have been enhanced in that study, and
the present study, due to the administration of moderate-fat snack 15 minutes after
progesterone administration, which has been reported to increase progesterone
bioavailability (Simon et al., 1993; Stanczyk, 1999).
A second aim of the study was to examine the neuropharmacological effects of
progesterone, alone and in combination with triazolam, using a drug discrimination
methodology. Progesterone alone did not substitute for the training dose of triazolam,
and concurrent progesterone administration did not alter the discriminative stimulus
effects of triazolam. These data do not suggest a common receptor mechanism of action
for progesterone and triazolam. It is possible that the sedative effects of progesterone
were not mediated by a GABAergic mechanism, although in vitro and pre-clinical in vivo
research has clearly documented GABAergic interactions between neurosteroids and
GABAergic agents, progesterone and its metabolites have also been shown to modulate
multiple receptor systems, including dopamine, serotonin, opiate, glutamate and nicotinic
acetylcholine receptor systems (Pluchino et al., 2006; Lena et al., 1993). However, other
interpretations are also plausible.

First, only a single, relatively small dose of

progesterone was tested. Progesterone may have engendered small, GABA-mediated
increases in the effects of the low doses of triazolam that were below the threshold
necessary to produce reliable drug-like responding on the drug discrimination task.
Second, it is possible that progesterone modulation of triazolam effects is dependent on
triazolam dose (Green et al., 1999). There is some evidence to support this possibility in
that progesterone effects on the highest triazolam dose (i.e., a shift in the time course of
the peak effects of the 0.25 mg/70 kg training dose) were distinct from those occurring at
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lower doses.

Because this shift was limited to the training dose of triazolam, this

enhancement would not have been detected due to the ceiling effect imposed by the
drug discrimination procedure. Third, it is possible that progesterone modulation of
triazolam effects is dependent on progesterone metabolites, rather than progesterone
per se (Lundgren et al., 2003; Majewska et al., 1986). The shift in peak effects of the
highest triazolam dose occurred after progesterone effects had dissipated and
progesterone metabolites, such as allopregnanolone, would be expected to peak,
supporting this possibility. Specifically, allopregnanolone levels increase 2 hours after
oral progesterone administration and remain elevated for up to 8 hours (Andréen et al.,
2006; Nahoul et al., 1993).

The interactions between progesterone and triazolam

documented in Study 2 and in previous studies also occurred at times corresponding to
the emergence of progesterone metabolites (McAuley et al., 1995).
The drug discrimination results of this study were not consistent with those of
Study 1 which demonstrated that the discriminative stimulus effects of triazolam were
potentiated during the mid luteal phase, when endogenous progesterone levels were
elevated. Several factors could have contributed to these disparate results, including the
presence of other neurosteroids, the duration of exposure to neurosteroids and
progesterone delivery. The current study used exogenous, oral progesterone, while the
previous study relied on naturally occurring changes in endogenous progesterone levels
across the menstrual cycle. The progesterone dose used in the current study was
selected to engender systemic progesterone levels comparable to those of the mid luteal
phase (Simon et al., 1993; Stanczyk, 1999). However, during the mid luteal phase, there
is a broader milieu of hormones of present, including estrogen and progesterone
metabolites, such as allopregnanolone (Genazzani et al., 1998). The relative influence
of estrogen on GABAergic drug effect is not clear. However, allopregnanolone is
neuroactive and a ligand at the GABA A receptor, and several cell culture and preclinical
studies have identified allopregnanolone as a key component in the hormonebenzodiazepine interaction at the GABAA receptor (Lambert et al., 2009; Paul & Purdy,
1992). The duration of exposure to neurosteroids may also have influenced sensitivity to
the discriminative stimulus effects of triazolam across studies. During the luteal phase of
the menstrual cycle, progesterone and allopregnanolone levels remain elevated for
approximately 10 days (Genazzani et al., 1998). This cycle-related chronic exposure to
neurosteroids may engender genomic-based increases in sensitivity to benzodiazepines
(Smith et al., 1998), which may have influenced the mid luteal phase enhancement of
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the discriminative stimulus effects of triazolam. In addition, the chronic exposure of
progesterone and its metabolites create steady blood levels of neurosteroids, whereas
blood levels after exogenous progesterone administration begin to decline 2 hours after
administration (Genazzani et al., 1998; Stanczyk, 1999). This difference in onset and
duration of action may also help explain why exogenous progesterone engenders a
drug-like effect, while similar levels of endogenous progesterone do not typically
engender subjective effects. A third factor that could have resulted in differential effects
across studies is progesterone delivery.

In the current study, progesterone was

administered orally, whereas the previous study relied on endogenous changes in
progesterone levels across the menstrual cycle.

Several studies have documented

inconsistent absorption of progesterone associated with oral dosing, with a 40 fold
magnitude of differences in absorption occurring across individuals (McAuley et al.,
1996; Simon et al., 1993).
This study examined the effects of progesterone, alone and in combination with
triazolam under conditions in which the time course of progesterone and triazolam
effects were concordant. Prototypical sedative-like effects of triazolam were observed,
and consistent with our previous study, progesterone alone also engendered statistically
significant increases in sedative-like effects on self-report and performance measures.
Progesterone and triazolam engendered additive effects on self-report and performance
measures when combined; however, progesterone did not substitute for the triazolam
discriminative stimulus, and concurrent progesterone administration had no effect on the
discriminative stimulus effects of triazolam. Future studies examining a wider range of
progesterone doses and progesterone metabolites in combination with both higher and
lower training doses of triazolam and longer-acting benzodiazepines would be useful to
further examine receptor-based interactions of progesterone and benzodiazepines.
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Table 3.1. F-values of selected measures for which a significant main effect or
interaction was obtained. No Triazolam x Progesterone or Triazolam x
Progesterone x Time interactions were detected.
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Figure 3.1. Mean triazolam-appropriate responding as a function of triazolam dose and
progesterone condition from assessments occurring at 150 minutes post-dose
during the control and test phases. Data points represent means of nine
participants. Uni-directional error bars represent 1 S.E.M.
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Figure 3.2. Mean ratings of VAS Drug Sedated (top row), VAS Performance Impaired
(middle row) and VAS Drug Effect (bottom row) as a function of progesterone
dose, triazolam dose and time following drug administration. The left column
presents triazolam effects after 0 mg progesterone and the right column presents
triazolam effects after 100 mg progesterone. Error bars omitted for clarity.
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CHAPTER 5
GENERAL DISCUSSION
The purpose of this series of studies was to determine whether the ovarian
hormone progesterone modulates the behavioral effects of the sedative drug triazolam
using human laboratory methodologies. The behavioral effects of triazolam and other
benzodiazepines are associated with the drugs’ positive modulation of the GABA A
receptor complex (Lelas et al., 2002; Licata et al., 2009; Rush et al., 1998).
Benzodiazepines function as discriminative stimuli in human models (Rush et al, 2003;
Vansickel et al, 2006; Kelly et al., 2003; Oliveto et al., 1992) and the discriminative
stimulus effects of benzodiazepines are sensitive to GABA A modulation (McMahon &
France, 2005a; 2005b; Lelas et al., 2000). The sensitivity of this paradigm allows for the
examination of the GABA-modulating effects of progesterone, which also exerts potent
effects on behavior via modulation of GABAA receptors (Rupprecht, 2003; Lambert et al.,
2009; Bertz et al., 1995; Paul & Purdy, 1992; Majewska, 1992; Majewska et al., 1986).
Overall, the results of these studies indicate that progesterone and its
neuroactive metabolites modulate the effects of triazolam. Changes in menstrual cycle
associated with increases in progesterone and exogenous progesterone administration
modified the effects of triazolam in pre-menopausal women. In addition, exogenous
progesterone, independent of triazolam, produced behaviorally active effects at lower
doses than have been previously been reported (Freeman et al., 1993; Soderpalm et al.,
2004; de Wit et al., 2001; van der Meer et al., 1982). When concordant peak effects of
progesterone and triazolam were examined, the combination of progesterone and
triazolam engendered additive effects on subjective and performance effects and
delayed the time at which the peak effects of the 0.25 mg/70 kg dose of triazolam
occurred; however progesterone did not consistently substitute for or modulate the
discriminative stimulus effects of triazolam. These effects suggest that the effects of the
parent hormone progesterone do not appear to be associated with the same
neuropharmacological mechanisms of action as triazolam.
OVERVIEW OF STUDY 1
The first study examined the discriminative stimulus, subjective, performance and
cardiovascular effects of triazolam across two phases of the menstrual cycle to
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determine if the hormonal milieu unique to each cycle phase would differentially
contribute to premenopausal women’s sensitivity to triazolam effects. The results of the
study clearly indicated that cycle phase modulated triazolam effects, such that during the
early follicular phase, the discriminative stimulus effects of all test doses (0.00, 0.06 and
0.12 mg/70 kg) were identified as placebo-like, while only the training dose (0.25 mg/70
kg) was identified as drug-like. In contrast, during the mid luteal phase, only placebo
and the low test dose (0.06 mg/70 kg) engendered placebo-like responding, whereas the
moderate dose (0.12 mg/70 kg) and the training dose were identified as drug-like.
These data suggest that sensitivity to the discriminative stimulus effects of triazolam
were modulated by menstrual cycle phase. However, the relative role of progesterone in
this interaction is not completely clear. Progesterone and other female sex hormones
are at nadir levels during the early follicular phase.

During the mid luteal phase,

progesterone levels are at their peak, but estrogen levels are also elevated throughout
this cycle phase. Therefore, even though there is very strong evidence from in vitro and
pre-clinical in vivo research to suggest that progesterone is a neuroactive steroid with
activity at the GABAA receptor, this study did not convincingly demonstrate that the
triazolam modulation observed was directly caused by elevations in progesterone.
OVERVIEW OF STUDY 2
Therefore, follow-up studies were conducted to further examine the potential
interaction between progesterone and triazolam. The goal of the second study was to
isolate and directly manipulate progesterone to determine if the changes in triazolam
effects observed previously during the mid-luteal phase were related to progesterone in
a dose-dependent manner.

The interactions between exogenous progesterone and

benzodiazepines had not previously been examined, so it was important to test a range
of doses of both progesterone and triazolam to determine whether interactions were
dose-dependent. As such, the second study examined the subjective, performance and
cardiovascular effects of a range of exogenous progesterone doses, alone and in
combination with a dose range of triazolam. The results of this study demonstrated that
both progesterone and triazolam, alone, produced sedative-like effects on subjective and
performance measures.

In addition, the combination of progesterone and triazolam

produced effects that were greater than those of either compound in isolation. The
results of this study build on those of the previous study, indicating that progesterone
alone, had significant effects on behavior at doses thought to engender blood levels
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occurring during the mid-luteal phase of the menstrual cycle, and enhanced the
behavioral effects of triazolam. The onset of peak effects and duration of effects of
progesterone, alone, were most consistent with the time course of the parent compound,
progesterone; whereas interactions with triazolam occurred later in time, and were likely
associated with increasing levels of progesterone metabolites.
However, even though the results of this study indicated an interaction effect
between progesterone and triazolam, due to the timing of dose administration, the peak
effects of progesterone and triazolam did not occur simultaneously. The interaction
between progesterone and triazolam occurred after the effects of progesterone alone
had dissipated. The time course of this interaction indicates that this study may not have
captured the potential magnitude of the interaction that may have occurred if the
simultaneous peak effects of progesterone and triazolam were examined. Furthermore,
it was not clear from these results the degree to which progesterone metabolites were
involved in the interaction.
OVERVIEW OF STUDY 3
Therefore, the final study in this series attempted to examine the interaction
between progesterone and triazolam under conditions in which the time course of the
onset and peak effects of the two compounds were relatively concurrent. In addition,
this study implemented drug discrimination methodology to examine whether
progesterone and triazolam share discriminative stimulus effects and whether
progesterone administration alters the sensitivity of the discriminative stimulus effects of
triazolam in order to further elucidate neuropharmacological mechanisms of action.
Consistent with the results of Study 1, triazolam functioned as a discriminative
stimulus and engendered prototypical sedative-like effects on subjective and
performance measures. Replicating the effects of Study 2, progesterone alone also
produced sedative-like effects on subjective and performance measures. However, in
contrast to Study 2, this study examined the simultaneous peak effects of progesterone
and triazolam. While additive effects of progesterone and triazolam were observed on
several measures, no evidence for pharmacological interactions was obtained.

In

addition, progesterone did not substitute for or modify the discriminative stimulus effects
of triazolam, suggesting that progesterone and triazolam do not share a common
receptor mechanism.
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The additive-like effects of progesterone and triazolam were detected on
subjective and performance measures, with the most notable effects occurring at the
moderate and high dose of triazolam (0.12 and 0.25 mg/70 kg). Furthermore,
progesterone shifted the time course of the effects of this dose to the right. Although no
interaction was observed, the progesterone-induced shift in time course was similar to
the effects observed in Study 2, suggesting that effects that are separate form the acute
effects of the parent hormone (e.g., production of progesterone metabolites) may be the
driving factor in the modulation of the behavioral effects of triazolam.
The results of these studies suggest that progesterone and its metabolites
modulate the behavioral effects of triazolam.

This series of studies used drug

discrimination to examine neuropharmacological mechanisms of action. The available
evidence suggests that the behavioral effects of progesterone, independent of its
primary metabolites, may occur through receptor mechanisms that are different from
those of triazolam.

Progesterone has been shown to modulate several receptor

systems, including serotonin (5-HT 3), dopamine, nicotinic acetylcholine, NMDA, sigma,
and oxytocin (Bullock et al, 1997; Wu et al., 1990; Rupprecht, 2003). It is unclear from
existing studies the degree to which any of these neurotransmitter systems are involved
in the behavioral effects of progesterone. However, a key component in the receptor
based hormone-benzodiazepine interaction may be progesterone metabolites. Several
studies have demonstrated that neuroactive progesterone metabolites, including
allopregnanolone, pregnanolone and TH-DOC, are ligands at the GABA A receptor, and
several cell culture and preclinical studies have identified these neurosteroids as a
driving factor of the modulatory effects of hormones at the GABA A receptor (Lambert et
al., 2009; Bertz et al., 1995; Paul & Purdy, 1992; Majewska, 1992; Majewska et al.,
1986). The effects of neuroactive progesterone metabolites may have contributed to mid
luteal phase potentiation of triazolam effects in Study 1, as levels of allopregnanolone
are elevated for approximately 10 days during the mid luteal phase (Genazzani et al.,
1998). In addition, the effects of progesterone metabolites may have also have
contributed to the effects observed in Study 2, as the interaction effects occurred at
times when progesterone metabolites emerge. Future studies will be required to more
fully elucidate mechanisms associated with progesterone’s behavioral effects and the
potential role of GABA as a mechanism through with progesterone metabolites might
modulate triazolam effects.
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LIMITATIONS
There were several limitations to these studies that warrant mentioning. First, in
Studies 1 and 3 the discriminative stimulus effects of triazolam were established without
respect to menstrual cycle phase. Sample and control sessions were conducted during
times when endogenous neurosteroids were at various levels, creating the possibility
that the magnitude of the of the discriminative stimulus was variable throughout training.
Although this may have occurred, the data do not indicate that cycle phase affected the
rate at which drug discrimination was acquired or the degree of sensitivity to
progesterone/cycle phase modulation in the test phase; however these studies were not
powered to examine this factor. Future research should examine if sample and control
sessions conducted during the mid luteal phase influence the degree of sensitivity to test
doses across the cycle.
A notable limitation in Studies 2 and 3 was the use of a limited dose range of
progesterone. An ideal dose range would have included a wider range of doses. The
lowest dose of progesterone (100 mg), used in both studies, produced sedative-like
effects on subjective and performance measures. Although much higher oral doses (600
to 1200 mg) and different routes of administration (e.g., intravenous and intramuscular)
that generate higher blood levels of progesterone have been shown to increase
subjective reports of sedation and fatigue (Soderpalm et al., 2004; de Wit et al., 2001;
Freeman et al., 1992; van der Meer et al., 1982), 100 or 200 mg oral progesterone had
not engendered sedative-like effects in previous studies (Evans & Foltin, 2006; Sofuoglu
et al, 2001; 2002).

A moderate-fat meal administered shortly after progesterone

administration had been shown to increase oral progesterone absorption (Simon et al.,
1993; Stanczyk, 1999; de Lignières, 1999), and may have increased behavioral
sensitivity to these doses.

Nonetheless, testing a full dose response curve of

progesterone, including sub-threshold doses, would have provided a more complete
assessment of the pharmacological interactions of progesterone and triazolam.
A limited dose range of triazolam was also used in each study. In particular,
Study 2 tested only two active doses of triazolam, both of which showed an interaction
with progesterone. Testing a sub-threshold dose (e.g., 0.06 mg/70 kg) would have been
useful to determine if progesterone could modulate a lower dose of triazolam. In
addition, Study 3 may have benefited from a lower training dose of triazolam. Consistent
drug-like responding only occurred in the presence of the training dose (0.25 mg/70 kg).
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Perhaps if a lower training dose had been used (i.e., 0.12 mg/70 kg), sensitivity to lower
doses of triazolam may have occurred, thereby allowing for the detection of more subtle
drug effects, particularly the effects of progesterone and progesterone modulation of
drug effects. Alternatively, it may have been useful to include a higher training dose of
triazolam as well. Progesterone enhanced and shifted the time course of the 0.25 mg/70
kg triazolam dose to the right. However, since this dose also served as the training dose,
a ceiling effect limited the possibility of detecting any progesterone enhancement of this
dose. A higher triazolam training dose would support more precise assessment of
progesterone effects on the 0.25 mg/70 kg dose.
The timing of the progesterone and triazolam doses in Studies 2 and 3 produced
somewhat different effects. In Study 2, progesterone was administered thirty minutes
prior to triazolam administration, which positioned the peak effects of triazolam to
coincide with the peak effects of progesterone metabolites, and an interaction effect was
observed.

In contrast, in Study 3, progesterone and triazolam were administered

simultaneously, which produced concurrent peak effects of triazolam and the parent
hormone progesterone, and no interaction was observed.

Future studies should

examine the discriminative stimulus effects of concordant peak effects of triazolam and
progesterone metabolites to determine if the presence of these metabolites would
modulate the discriminative stimulus effects of triazolam, which may more thoroughly
address whether there are common receptor-based mechanisms of action between
progesterone metabolites and triazolam.
Another limitation of these studies was the lack of pharmacokinetic data. Blood
levels of triazolam, progesterone, and progesterone metabolites would have provided
valuable information regarding the accuracy of menstrual cycle phase determinations,
the time course of progesterone and its metabolites, the degree to which progesterone
was absorbed, and the degree to which triazolam pharmacokinetics were altered in the
presence of progesterone and its metabolites.

Future studies should examine the

manner in which blood levels of progesterone and its metabolites correlate with the
sensitivity to triazolam, both across the cycle and after exogenous progesterone
administration.
In addition, the population for each study was limited to pre-menopausal adult
women. Moreover, in Studies 2 and 3, only women taking certain forms of oral birth
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control (e.g., formulations containing a 7 day placebo phase) were included. These
populations have had chronic exposure to progesterone, either through oral birth control
regimens or through the mid luteal phase of the menstrual cycle. Given that the effects
of repeated exposure to progesterone have been shown to change cellular signaling and
developmental brain structure and function, it would be interesting to test a broader
range of study populations to further understand the biological underpinnings of the
hormone-benzodiazepine interaction.
Another limitation was that sample sizes were limited in each study. Although
within subject design allows for detection of drug effects with relatively few participants
and significant effects of both progesterone and triazolam were observed across studies,
a larger sample size may have increased the ability to detect subtle drug interactions
and/or individual differences in the sensitivity to progesterone and/or triazolam.
Another factor that may have influenced these results is the metabolic interaction
between progesterone and triazolam.

Pre-clinical research has indicated that

GABAergic drugs such as benzodiazepines and ethanol (as well as non-GABAergic
medications such as atypical antipsychotics) induce the production of progesterone and
its metabolites (Aouad et al., 2009; Barbaccia, 2004). However, it is not clear to what
degree this neurosteroid increase results in changes in drug effects.
Lastly, it is unclear the degree to which the results of these studies were
influenced by the genomic effects of neurosteroids. Although the non-genomic, receptor
mediated effects of progesterone are well documented, neurosteroids also have effects
on genomic processes that could alter drug effects. For example, rapid changes in
blood levels of neurosteroids can alter the degree of gene expression for the α 4 GABAA
subunit.

Rapid decreases in allopregnanolone increase gene expression, while

increases in allopregnanolone decrease gene expression for the α 4 GABAA subunit
(Rupprecht, 2003; Smith et al., 1998; Grobin & Morrow, 2000). Pre-clinical models (both
in vitro and in vivo) suggest that expression of the α 4 subunit influences relative
sensitivity to benzodiazepines, with increased gene transcription leading to decreased
sensitivity to benzodiazepines and decreased gene expression increasing sensitivity to
benzodiazepines (Smith et al., 1998; Grobin & Morrow, 2000). Although the time course
of these genomic effects in humans is unclear, pre-clinical models have demonstrated
changes in GABAA-mediated seizure susceptibility 24 hours after neurosteroid
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manipulations (Smith et al., 1998). Additional research is necessary to determine the the
time course of genomic modulation of GABAA receptor composition in humans.
IMPLICATIONS
Despite these limitations, these series of studies established that progesterone
plays a role in the behavioral effects of triazolam. To build on these results, future
research should further examine the mechanism of action of progesterone at the GABA A
receptor. Although the behavioral effects of neurosteroids are thought to result from their
action at steroid-specific site on the GABA A receptor, this effect has been difficult to
establish, as there are no competitive antagonists available that block the action of
GABAA modulators that act at steroid-specific binding sites or to block the metabolism of
progesterone, thereby allowing for the independent examination of the effects of
progesterone and its metabolites.

However, pre-clinical research examining the

discriminative stimulus effects of neurosteroids, benzodiazepines and negative GABA A
modulators provide evidence for a separate binding site for neurosteroids and
benzodiazepines at the GABAA

receptor.

For example, pre-clinical models have

demonstrated that pregnanolone, a neuroactive progesterone metabolite, substitutes for
the discriminative stimulus effects of midazolam; however certain negative GABA A
modulators (β-CCE and β-CCM) block this substitution while leaving the discriminative
stimulus effects of midazolam intact.

Alternatively, other antagonists/negative

modulators (flumazenil, Ro-1545-13) leave pregnanolone substitution intact, but block
the discriminative stimulus effects of midazolam (McMahon & France, 2005b; McMahon
et al., 2001).

This selective blockage of neurosteroid and benzodiazepine effects

indicates that although their mechanisms of action at the GABA A receptor are similar (as
evidenced by the substitution profile), the exact receptor-level mechanisms are
distinguishable and likely occur through slightly different mechanisms. Future research
should examine the discriminative stimulus effects of allopregnanolone, alone and in
combination with a benzodiazepine in women and determine if negative GABA A
modulators act in a similar manner to selectively block the discriminative stimulus effects
of each compound, in order to further clarify the neurobiological basis of the interaction
in humans.
Although the pre-clinical research has suggested GABAergic mechanism for
neurosteroids, the data from these studies, specifically Study 3, indicate that
progesterone effects were not exclusively mediated by its action at the GABA A receptor.
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The neurobiological basis of the sedative-like effects of progesterone are unclear, as
progesterone engendered subjective and performance effects, but did not modulate or
substitute for the discriminative stimulus effects of triazolam. As progesterone has also
been shown to modulate several other neurotransmitter systems (Bullock et al, 1997;
Wu et al., 1990; Rupprecht, 2003), future research should examine the degree to which
progesterone substitutes for the discriminative stimulus effects of drugs acting at
serotonin (5-HT3), dopamine, nicotinic acetylcholine, NMDA, sigma, and oxytocin
receptors. Alternatively, applying medications that act as antagonists at these receptors,
as well as selective negative GABA A modulators, in combination with progesterone,
could also help to determine the neurobiological mechanisms that contribute to its
behavioral effects.
Taken together, the results of these studies have clinical importance, as they
demonstrate that drug effects can be influenced by ovarian hormones. This information
is important when considering women’s health, as the effects of centrally acting
medications may not have static effects across the menstrual cycle, during adolescence,
or during menopause, as these all reflect times when hormone levels are rapidly
changing. Knowledge of this effect has led to cycle-based modifications in GABAergic
medication regimens for women being treated for epilepsy (Reddy, 2009; Herzog et al.,
2009; Bäckström, 1976). In addition, doses of certain types of anaesthesia medications
are also titrated based on levels of endogenous neurosteroids (Erden et al., 2005).
Future research should determine if dose modifications might be necessary for other
GABAergic medications as well.
Importantly, additional research is also necessary to determine if menstrual cycle
changes influence drug abuse liability in women, as it is not known if the reinforcing
effects of certain drugs may change as a function of menstrual cycle phase. Variation in
levels of endogenous neurosteroids, both within and between individuals, may also
occasion individual differences in the effects of drugs of abuse. Rapidly increasing levels
of neurosteroids (i.e., beginning of the luteal phase, during female adolescence), or
abrupt declines in neurosteroid levels (i.e., late luteal phase, peri-menopause and
menopause) may enhance or attenuate acute pharmacological effects, thereby
potentially altering the functional effects of drugs. Recognizing the degree to which
hormone variations influence drug effects may help identify gender differences in drug
abuse liability.
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Hormonal modulation of drug effects may be an important factor in men’s
sensitivity to drug effects as well. Although hormonal milieu is not typically thought to
contribute differences in acute drug effects in men, there are data suggesting that
exogenous neurosteroids have similar subjective effects in men and women and similar
discriminative stimulus effects in male and female animals (Grant et al., 2008;
Söderpalm et al., 2004).

It is not clear if an interaction between exogenous

neurosteroids and GABAergic drugs would occur in men, but future research should
examine this possibility, as it would provide insight into the mechanisms that occasion
the interaction and would clarify if developmental brain structure unique to each sex or if
chronic exposure to neuroactive steroids (via the menstrual cycle phase) are necessary
mediators in the interaction. This information would also inform men’s health and
susceptibility to drug use. For example, it is unclear the degree to which men with
elevated levels of endogenous neurosteroids (occurring through natural variations or in
disease states) may display sensitivity to GABAergic drug effects.
The manner in which progesterone interacts with GABAergic medications in a
variety of populations becomes increasingly important as progesterone becomes more
popular as a prescribed therapeutic. Progesterone is currently prescribed to women for
hormone replacement therapy, infertility, amenorrhea and epilepsy (Mahmud, 2009;
Check, 2009; Whitehead et al., 1990; Reddy & Rogawski, 2009). In addition, clinical
trials

have

been

conducted

using

chronic

progesterone

therapy

as

a

pharmacotherapeutic for the treatment of cocaine abuse in men (Sofuoglu et al., 2007).
Current clinical trials are also being conducted to determine if very large doses of
intravenous progesterone can decrease the neuronal damage associated with traumatic
brain injury (Wright et al., 2007). Endogenous levels of neurosteroids are also taken into
account when formulating drug regimens for women who are diagnosed with epilepsy,
specifically catamenial epilepsy, a condition in which hormone levels are associated with
risk of seizure.

Neurosteroids act as anti-epileptics and rapid decreases in these

hormones decrease seizure threshold (Biagini et al., 2010).

Doses of anti-epileptic

medications are often adjusted to accommodate fluctuations of endogenous hormones,
with increases in medication doses occurring during times when progesterone levels are
minimal (follicular phase, late luteal phase) to reduce the possibility of seizures (Biagini
et al., 2010).

In addition, new therapies are being developed in which exogenous

neurosteroids (progesterone, allopregnanolone and synthetic derivates of these
hormones) are administered to help control the frequency of catamenial seizures (Reddy
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& Rogawski, 2009). Information regarding the degree to which progesterone modulates
GABAergic function in both men and women and the subsequent interaction with
benzodiazepine and barbiturate medications and alcohol may become increasingly
important as these lines of treatment develop.
Taken together, data from these and similar studies will be helpful in the
identification of individual differences in drug effects and will assist in formulating of
gender-specific prevention or treatment techniques.
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